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Abstract 
Our understanding of adipose tissue as an endocrine organ has been transformed over the last 
twenty years. During this time a number of adipocyte-derived factors or adipokines have been 
identified. This paper will review evidence for how adipokines acting via the central nervous 
system (CNS) regulate normal physiology and disease pathology. The reported CNS-mediated 
effects of adipokines are varied and include the regulation of energy homeostasis, autonomic 
nervous system activity, the reproductive axis, neurodevelopment, cardiovascular function, and 
cognition. Due to the wealth of information available and the diversity of their known functions, the 
archetypal adipokines leptin and adiponectin will be the focused on extensively. Other adipokines 
with established CNS actions will also be discussed. Due to the difficulties associated with 
studying CNS function on a molecular level in humans, the majority of our knowledge, and as 
such the studies described in this paper, comes from work in experimental animal models; 
however, where possible the relevant data from human studies are also highlighted. 
Didactic Synopsis 
Major Teaching Points: 
1. In addition to storing excess energy as triglyceride, adipose tissue is an important 
endocrine organ secreting factors called adipokines into the circulation that act on their 
receptor targets in distant tissues, including the CNS. 
 
2. Leptin is a key adipokine which acts on target receptors throughout the brain to signal 
how much energy the body has stored. 
 
a. Obesity (excess adipose tissue) is associated with high levels of circulating 
leptin. 
b. Reduced circulating leptin is a key signal for the activation of CNS pathways 
which promote weight gain, including increased food intake and reduced energy 
expenditure. 
c. Leptin acting in the brain also regulates the activity of other neuroendocrine axes 
including the reproductive axis and the thyroid hormone axis, and can also 
regulate cardiovascular function. 
 
3. Other adipokines that act in the CNS to modulate physiological processes include 
adiponectin, resistin, apelin, visfatin and adipocyte-derived cytokines. 
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Introduction 
In the past twenty years there has been a transformation in our understanding of adipose tissue 
as an endocrine organ. Numerous adipocyte-derived cell signaling proteins, or adipokines, have 
been identified that have critical functions in normal physiology and pathophysiology. The goal of 
this paper is to provide an overview of the site and mechanism of action of some of the key 
adipokines in the central nervous system (CNS), focusing on those with the most well defined and 
widespread CNS actions. The sheer diversity and number of adipokines that have been identified 
means that it would be beyond the scope of this review to feature them all, and any omissions 
should not be taken as indication that these factors are not considered important but as a 
reflection of a desire to provide a comprehensive overview of the adipokines that have the most 
diverse and currently well-characterized CNS actions, specifically leptin and adiponectin. Due to 
the difficulties associated with studying CNS function on a molecular level in humans, the majority 
of our knowledge, and as such the studies described in this paper, comes from work in 
experimental animal models; however, where possible the relevant data from human studies are 
also highlighted. 
A list of abbreviations used in this paper can be found in table 1. 
Leptin 
Leptin is arguably the prototypical adipokine. Originally identified in 1994 as the product of the 
obese (ob) gene, leptin is evolutionarily conserved across mammalian and non-mammalian 
species (637). The white adipose tissue (WAT) expression of the ob gene is regulated by energy 
status, being upregulated by increased adiposity associated with obesity (positive energy 
balance) (195, 240, 366, 376) and decreased by negative energy balance associated with fasting 
(195, 569). There is also evidence that leptin (ob) gene expression in WAT is diurnally regulated 
(498). Leptin is secreted into the blood where, in mammals, circulating levels are a reflection of 
the amount of WAT stored (377): the more WAT stores, the more circulating leptin. Indeed, 
reduced levels of circulating leptin associated with weight-loss is a key signal for the activation of 
CNS pathways which promote weight gain, including increased food intake and reduced energy 
expenditure (313, 475, 489). The discovery of leptin gave great hope for the development of a 
potential specific therapeutic target for obesity. Indeed, early promising studies demonstrated that 
exogenous administration of leptin into lean and diet-induced obese (DIO) rodents reduces food 
intake and body weight (83, 235, 452). However, evidence rapidly emerged that the high 
circulating levels of leptin associated with obesity were both a cause and consequence of 
resistance to the effects of the hormone on appetite and metabolism (195).  
Even before the cloning of leptin evidence suggested the existence of an adipose-derived 
circulating factor that could regulate feeding behavior by acting in the brain (121, 278). After the 
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cloning of leptin, this was supported by data indicating that radiolabeled leptin bound at high-
levels in the hypothalamus of the rodent brain and that exogenous leptin treatment normalized 
the elevated hypothalamic neuropeptide Y (NPY) gene expression in leptin-deficient obese ob/ob 
mice (539). The importance of the hypothalamus as a key site of leptin action was confirmed 
when the leptin receptor was identified and cloned in 1995 (555).  
Due to the critical importance of adequate energy reserves for numerous physiologic processes 
one of the key integrative roles of leptin, which will be described in more detail in the sections 
below, is as an indicator of sufficient energy availability/reserves, as the circulating levels of this 
hormone drop rapidly during fasting which in turn modulates the activity of a number of 
neuroendocrine axes (8). 
 
Leptin receptor signaling 
There are six alternatively spliced forms of the leptin receptor (Ob-Ra-f) that have been identified 
(345, 592). These are all single transmembrane spanning proteins, with the exception of Ob-Re 
which is predicted to be a soluble protein (345). Of these the full-length or long-form receptor (Ob-
Rb), the only variant with a long intracellular domain sufficient for downstream signaling, is 
believed to be the principal signaling form (41, 214, 345). Ob-Rb is a type 1 cytokine receptor. 
Upon leptin binding to the extracellular domain of the receptor dimer, Janus kinase (JAK) 2 is 
activated, resulting in phosphorylation of the intracellular domain of receptor at three tyrosine 
residues – Tyr985, Tyr1077 and Tyr1138, each of which mediate distinct downstream signaling 
events (figure 1): 1) Phosphorylation of Tyr985 resulting in recruitment of Src-homology 2 
domain-containing phosphatase 2 (SHP2/PTPN1) leading to activation of the extracellular signal-
regulated kinases (ERK) signaling cascade (27, 89, 357); 2) Phosphorylation of Tyr1077 resulting 
in recruitment of the transcription factor signal transducer and activator of transcription (STAT) 5 
(219) and 3) Phosphorylation of Tyr1138 resulting in recruitment of the transcription factor STAT3 
(27, 357, 579). Indeed, activation/phosphorylation of STAT3 (pSTAT3) is a commonly used 
experimental marker of leptin receptor activation/activity in vivo and in vitro (579). Activation of 
leptin receptor signaling also can result in activation of the phosphatidylinositol 3-kinase (PI3K) 
pathway via insulin receptor substrate (IRS) proteins (160, 480). In the course of normal 
homeostasis, negative feedback inhibition of Ob-Rb signaling is provided by suppressor of 
cytokine signaling (SOCS) 3 (53, 55, 164) binding at Try985 and PTP1B acting at JAK2 (106, 
628). Genetic technologies have enabled determination of the relative physiological significance 
of activation of different signaling pathways downstream of the leptin receptor. These will be 
addressed in each of the relevant sections below. 
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In the rest of the document any reference to “leptin receptor is signaling” typically is relating to the 
full-length or long-form receptor (Ob-Rb) unless stated otherwise. 
 
Leptin receptor expression in the CNS 
Within the rodent brain early in situ hybridization studies revealed that Ob-Rb mRNA is highly 
expressed in the hypothalamus (398) and that this receptor is activated by exogenous leptin 
treatment (579, 609). Subsequent studies have revealed a more widespread distribution of leptin 
receptors across the CNS (180) fitting with its diverse functions (table 2). In situ hybridization 
studies have revealed a distinct CNS distribution of the different leptin receptor isoforms, with Ob-
Ra and Ob-Rb being the principal forms expressed in the hypothalamus and OB-Ra, OB-Rc and 
OB-Rf predominating in the choroid plexus (226). The use of transgenic technologies has 
enabled animals with fluorescently tagged leptin receptors to be created, which has facilitated 
detailed studies mapping CNS sites of leptin receptor expression and their downstream targets to 
be mapped (449, 508).  
Although outside of the CNS, of relevance to topics to be discussed later in this review, leptin 
receptors are also expressed on the nodose (inferior) ganglion of the vagus nerve (76, 79). 
Leptin receptors are found on a variety of different neuronal populations in the brain (table 2). 
This widespread distribution contributes to its role as a neuromodulator of numerous 
neuroendocrine and non-neuroendocrine pathways, which will be described in more detail later in 
this review. Specific deletion of leptin receptors from different neuronal populations has 
differential effects on physiology which will be described in the relevant sections below. While the 
majority of work on CNS targets of leptin has focused on neurons, leptin receptors are also found 
on non-neuronal cells in the CNS including astrocytes (110, 272, 442), microglia (455), tanycytes 
(23), endothelial cells (54, 217), and choroid plexus epithelial cells (146, 398). 
  
Leptin entry into the brain 
In order to mediate its effects via the centrally expressed receptors leptin needs to enter the CNS. 
The blood-brain barrier (BBB) functions to protect the brain from fluctuations in the body and 
helps to maintain the microenvironment in the CNS. Made up of endothelial cells which line the 
cerebral microvessels, the function of the BBB is regulated by the interaction of endothelial cells 
with other cellular components of the ‘neurovascular unit’ including astrocytes and neurons (1). 
The BBB regulates movement of substances including nutrients and hormones, including leptin, 
in and out of the brain.   
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Proximal to the cerebral ventricles are circumventricular organs within the brain. Whist there is 
some debate surrounding the number of circumventricular regions in the mammalian brain, major 
sites include the median eminence (ME) and adjacent neurohypophysis, organum vasculosum 
lamina terminalis, subfornical organ (SFO) and the area postrema (AP) (167). In these small 
regions of the brain, the BBB of cerebral microvessels is more readily permeable, facilitating 
communication between the brain and cerebrospinal fluid (CSF), and factors circulating in the 
blood. Evidence suggests that portions of the ME within the hypothalamus lack the normal protein 
components of the BBB, suggesting an absence of the normal barrier in this area (71, 426). Of 
significance to the CNS actions of leptin, data indicates that a population of hypothalamic arcuate 
(ARC) neurons adjacent to the ME project outside of the BBB and are able to rapidly respond to 
peripherally administered leptin, as assessed by expression of pSTAT3 (185). As such, 
circumventricular organs are critical sites of entry for adipokines in the brain and are important for 
their centrally mediated effects (199).  
Understandably, due to the importance of the hypothalamus in the regulation of energy 
homeostasis, the ME has been the focus of most studies examining the entry of leptin into the 
brain. However, it is important to note that the choroid plexus (146), SFO (528) and AP (250, 400) 
are also sites at the blood-brain and/or brain-CSF interface that are also directly responsive to 
leptin and may mediate some of its CNS effects. 
The CNS is the principal site of action of leptin mediating many of its known physiological effects. 
Early studies, shortly after its cloning, tracing the entry of radiolabeled leptin into the brain 
indicated that 75% of circulating 
125
I labelled leptin enters the brain (32). Major sites of entry of 
leptin in to the CNS include the choroid plexus and ME (32, 146). Leptin receptors are expressed 
on cerebral endothelial cells of both rodents and humans (54, 217). While obesity is associated 
with increased circulating leptin, leptin transport into the brain and subsequent CSF levels of 
leptin are not concomitantly increased, suggesting that leptin transport into the brain is saturable 
(77, 87). This saturable transport mechanism is one proposed cause of leptin-resistance 
associated with obesity, which will be discussed in greater detail later in this review. In addition to 
obesity, a number of factors and physiological states have been shown to influence leptin 
transport into the CNS, shown in table 3. 
 
CNS Leptin Resistance 
CNS leptin-resistance is characterized by a loss of physiological responsiveness to leptin despite 
the high circulating levels seen in both obese individuals and animals (without congenital leptin 
deficiency), and was recognized early after the leptin gene was first cloned (195). While obesity is 
associated with chronic elevations in circulating leptin (235), it is debated whether leptin 
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resistance is a cause or consequence of obesity (416), or quite likely both. Within the 
hypothalamus, there is evidence to suggest that leptin-resistance associated with diet-induced 
obesity is more pervasive in the ARC than other nuclei, including the ventromedial hypothalamus 
(VMH), dorsomedial hypothalamus (DMH) and lateral hypothalamic area (LHA) (387, 413), likely 
due to its proximity to the ME causing this region to be readily exposed to the high circulating 
levels of leptin and proinflammatory cytokines derived from WAT of obese animals. Interestingly, 
the ventral tegmental area (VTA), which is a key component of the dopaminergic reward pathway, 
also shows leptin-resistance in response to diet-induced obesity in rats (387). Improving CNS 
leptin sensitivity is seen as a potential therapeutic target for metabolic disease, and as such there 
is extensive interest in understanding the molecular mechanisms behind this phenomenon. A 
combination of defective leptin signaling and impaired entry of leptin into the CNS are both 
thought to be contributing factors (170).  
Recent evidence suggests that mimicking obesity-associated elevations in circulating leptin by 
chronically infusing leptin into wild-type lean mice is not sufficient to induce leptin resistance 
regardless of the nutritional state of the animal (fed/fasting) (476). This indicates that other 
pathophysiological changes associated with obesity are likely contributing to the development of 
leptin-resistance. Candidates include inflammation and endoplasmic reticulum (ER) stress. 
Diet-induced obesity causes inflammation and ER stress in the brain, with the hypothalamus 
being the predominantly studied region in this regard (143, 438, 561, 635). Supporting a potential 
role of ER stress as a causative factor in the development of central leptin-resistance, induction of 
ER stress using genetic and pharmacologic tools is sufficient to induce leptin-resistance in vitro 
(438) and in vivo within the hypothalamus (438, 608) as assessed by a reduction in leptin induced 
phosphorylation of STAT3. This is supported by the finding that treatment with compounds that 
enhance ER function, 4-phenyl butyrate (PBA) and tauroursodeoxycholic acid (TUDCA), 
improves leptin-sensitivity in genetic (ob/ob) (438) and diet-induced (608) mouse models of 
obesity. 
In common with inflammatory signaling, induction of hypothalamic ER stress activates the nuclear 
factor-kappa B (NFκB) signaling pathway and pharmacological inhibition of ER stress reduces 
high-fat diet-induced hypothalamic activation of the NFκB signaling cascade (635). This suggests 
that activation of NFκB signaling is an important downstream mediator of ER stress in this 
context. In the same study, virally mediated activation of NFκB signaling in the hypothalamus was 
sufficient to induce leptin-resistance in lean mice while inhibition of NFκB signaling, specifically in 
agouti-related protein (AgRP) neurons of the medial basal hypothalamus, reduced high-fat diet 
induced weight gain and leptin-resistance (635). Interestingly, in contrast, chronic activation c-Jun 
N-terminal kinases (JNKs) but not NFκB signaling specifically in AgRP neurons is sufficient to 
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stimulate obesity and leptin resistance (572), indicating that different hypothalamic neuronal 
populations may have distinct roles in the response to inflammation. Upstream of NFκB signaling, 
the adaptor protein MyD88 and its associated receptor toll-like receptor 4 (TLR4) are important 
for mediating leptin-resistance associated with high-fat feeding by direct central administration of 
saturated fatty-acids (18, 317). 
As described above, in the course of normal homeostatic leptin signaling, negative feedback 
inhibition of Ob-Rb signaling is provided by SOCS3 (53, 55, 164) and PTP1B binding (106, 628). 
Obesity is associated with elevated hypothalamic expression of both SOCS3 (53) and PTP1B 
(629) and genetic deletion of SOCS3 and PTP1B binding from the CNS or specifically from 
proopiomelanocortin (POMC) neurons in the hypothalamus protects against high-fat diet-induced 
leptin-resistance (44, 307, 405). Together these findings suggest that SOCS3 and PTP1B may 
also play a role in the development of obesity associated leptin-resistance. Expression of SOCS3 
(536) is induced via transcriptional activation of STAT signaling; however, in the case of obesity 
leptin induced phosphorylation of STAT3 is decreased (170), which suggests that alternative 
(non-STAT3 mediated) pathways are likely to be contributing to the upregulation of SOCS3 in this 
context. Additionally, expression of PTP1B is increased by inflammation (629) and ER stress 
(443) via the activation of NFκB signaling suggesting a potential mechanistic link between 
inflammatory signaling and ER stress and the development of CNS leptin-resistance. The 
potential molecular signaling mechanisms underlying the development of CNS leptin-resistance 
are summarized in figure 1. 
One of the challenges in studying mechanisms of leptin-resistance in experimental animal models 
is that intervention (genetic or pharmacological) associated improvements in leptin resistance are 
typically associated with weight-loss or a failure to gain weight when exposed to an obesogenic 
diet; thus, it often is difficult to differentiate whether the reduced leptin-resistance is due to the 
reduced weight gain or vice versa. These challenges are elegantly discussed in a 2010 review by 
Myers and colleagues (416). 
Impaired entry into the brain has been proposed as another potential mechanism underlying CNS 
leptin resistance (170). As described above, a recent study by Balland and colleagues (23) has 
demonstrated that intact leptin receptor signaling in tanycytes is critical for leptin entry into the 
CNS and that this is defective in obese animals (both diet-induced and genetic). This provides a 
molecular basis linking both underlying tenets of CNS leptin resistance: defective leptin signaling 
and impaired entry of leptin into the CNS. Whether similar pathological stimuli, namely 
inflammation and ER stress, impair tanycyte mediated leptin transport into the CNS remains to be 
fully determined. 
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Importance of leptin in development of neural circuitry 
A number of pieces of evidence support an important role for leptin in the development of neural 
circuitry. Early studies in obese mice with congenital leptin deficiency (ob/ob mice) showed that 
these animals have fundamental differences in the macrostructure of their brains, including 
decreased brain weight and volume, and impaired organization of dendrites within the 
hypothalamus (48, 49). The reduction in brain weight in ob/ob mice can be reversed by leptin 
treatment from 4-weeks (5, 541), suggesting a key role for leptin in brain development. Although 
rare in humans, congenital leptin deficiency is associated with changes in brain size and structure 
which can be reversed, at least, in part by leptin treatment (365, 389).  
Leptin receptors are expressed in the brain (leptomeninges and choroid plexus) from early in 
embryonic development [E13.5 in the mouse (262)]. There is a post-natal surge in leptin levels in 
rodents, independent of adipose mass, starting at post-natal day 4 and peaking at post-natal day 
10, which does not concomitantly impact energy homeostasis but is believed to act as a 
developmental cue (7). In mice, hypothalamic circuitry key for the regulation of energy 
homeostasis is not fully developed at birth but the intra-hypothalamic and extra-hypothalamic 
projection develops rapidly becoming mature by around post-natal day 16-18 (65, 66). The 
development of the intra-hypothalamic projections from the ARC to the paraventricular nucleus of 
the hypothalamus (PVH) are attenuated in mice with defective leptin signaling [leptin-deficient 
ob/ob mice (66) and db/db mice with dysfunctional leptin receptors (65)], which may provide a 
neuroanatomic basis for many of the neuroendocrine abnormalities seen in these animals. 
Mimicking the post-natal leptin surge by leptin injection into the leptin-deficient ob/ob mice was 
sufficient to partially restore the ARC to PVH neuronal projections supporting a critical role for the 
post-natal leptin surge in the development of hypothalamic neuroendocrine circuitry (66). Indeed, 
in vitro experiments in organotypic hypothalamic slices from post-natal brains demonstrated leptin 
to be a potent neurotrophic factor (66). Administration of leptin in adult animals was not able to 
restore these critical projections, emphasizing the importance of leptin during this key stage in 
CNS development.  This is further strengthened by data indicating that inhibiting the neonatal 
leptin surge using a leptin antagonist in wild-type rats alters hypothalamic gene expression of 
neurotrophic factors and intermediate filament proteins (nestin and vimentin) (367, 395), 
implicated in growth and survival of neural cells. Interestingly, these effects appear to be sexually 
dimorphic during the neonatal period and also with respect to their phenotypic manifestations in 
the adult animal (367, 395). 
POMC and AgRP neurons of the ARC, which are critical for the regulation of energy homeostasis 
(530), send projections to the PVH. In line with previous studies, leptin deficient ob/ob mice show 
reduced AgRP and POMC fiber density (as assessed by α-melanocyte stimulating hormone 
[αMSH] immunoreactivity) in regions of the PVH containing both neurosecretory and pre-
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autonomic neurons (68).  Significantly, post-natal leptin treatment in leptin-deficient ob/ob mice 
partially restores ARC to PVH projections of AgRP but not POMC neurons in regions of the PVH 
containing pre-autonomic neurons (68), pointing to a differential regulation of the development of 
these important neuronal pathways by leptin. In contrast, perhaps surprisingly, leptin treatment 
was not able to regulate either POMC or AgRP inputs on to PVH neurosecretory neurons in ob/ob 
mice, indicating a differential role of leptin in the development of hypothalamic autonomic 
compared with neurosecretory circuitry. Indeed, these anatomical findings are supported by 
physiological data indicating that ob/ob mice treated with leptin from post-natal day 4-14 show a 
modest improvement in the phenotypic manifestations of their autonomic deficits including a 
modest reduction in food intake, body weight, adipocyte size and thermogenic response to cold 
exposure (68).  In addition to impacting neurons, recent data suggests that post-natal leptin 
treatment can also impact the proliferation of hypothalamic astrocytes, which may in turn 
influence synaptic function and connectivity within the hypothalamus during this critical 
developmental stage (491). 
In the absence of congenital alterations in leptin-signaling, acquired early disruptions in leptin 
signaling associated with leptin-resistance caused by post-natal over-nutrition [small litter size] 
(67, 215), or neonatal exposure to obesity or diabetes (537) also impacts development of the 
hypothalamic circuitry regulating energy homeostasis. 
The development of mice with defects in specific signaling pathways downstream of leptin 
receptor activation has enabled genetic dissection of the leptin receptor signaling pathways 
mediating the actions of leptin on hypothalamic development. Leptin-induced activation of STAT3 
and ERK signaling appear to be important for control of projections from ARC neurons to the PVH 
(64).  
In addition to hypothalamic development there is evidence to suggest that leptin signaling may 
also be important for the development of other key circuits in the brain including those regulating 
cognition and emotion. Absence of leptin-signaling in db/db or ob/ob mice is associated with 
complex changes in response to neurobehavioral testing characteristic of memory deficits, 
depression and an altered anxiety profile (361, 516, 616). Alterations in these behavioral 
paradigms can be representative of alterations in hippocampal function. Indeed, further 
examination has revealed that db/db mice have reduced dendritic spine density in dentate gyrus 
(544), CA1 and CA3 neurons (147) within the hippocampus which may account for the 
neurobehavioral deficits seen in these animal models. Furthermore, congenital defects in leptin 
receptor signaling in both db/db mice and Zucker rats cause impaired hippocampal long-term 
potentiation (LTP) (212, 361). Together these data suggest an important role for leptin in synapse 
development in the hippocampus which impacts its function. A role for leptin in modulating 
hippocampal function will be discussed further later in this review. 
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Effects of leptin on energy and glucose homeostasis 
The most well described physiologic roles of leptin are in the regulation of energy homeostasis. 
Leptin impacts energy homeostasis on multiple levels including regulating food intake, energy 
expenditure, thermogenesis and glucose homeostasis. Loss of leptin-signaling in rodents (122, 
211, 285, 570, 571) and humans (404) results in profound dysregulation of energy homeostasis 
characterized by obesity, increased food intake, insulin resistance and altered energy expenditure 
including impaired thermoregulation. Genetic dissection of the leptin-signaling pathways critical 
for glucose and energy homeostasis has revealed a key role for a number of proteins including 
STAT3 (37-39), STAT5 (450), PI3K (423, 638). Moreover, loss of inhibition of leptin signaling 
through modulation of SOCS3 binding site (Tyr985) results in mice which are leaner than their 
wild-type littermates (56).  
AMP-activated protein kinase (AMPK) is key cellular mediator of energy homeostasis found in 
both neurons and glia in the CNS (for review see (385)). AMPK activity is increased in times of 
energy deficit, acting to conserve cellular energy by switching off unnecessary energy consuming 
pathways and promote ATP production (244). In vivo leptin treatment decreases AMPK activity in 
both the hypothalamus (403) and caudal brainstem (249). Furthermore, genetic or 
pharmacological stimulation of AMPK activity in the hypothalamus or brainstem is sufficient to 
attenuate the inhibitory effects of leptin on food intake (249, 403, 554) suggesting that 
suppression of AMPK activity is a key downstream cellular mediator of leptin-signaling in the 
CNS. In addition to modulating food intake, AMPK has also been implicated in mediating leptin-
induced sympathetic nerve activation (554) suggesting that AMPK action may also impact the 
effects of leptin on thermogenesis, cardiovascular and renal function. 
The roles of different discrete neuropeptides in mediating the downstream effect of leptin on 
energy homeostasis have been studied extensively using both genetic and pharmacologic studies 
in rodents, and will be discussed further below. However, as these neuropeptides typically have 
restricted distribution these studies have resulted in elucidation of discrete leptin-regulated 
circuits in the CNS and the potentially functional overlap/redundancy between these circuits is not 
always clear. Other studies have taken a different approach and have sought to determine the 
broader common critical downstream consequences of leptin signaling that are critical for the 
regulation of energy homeostasis. Taking a wider overview, the work of Vong and colleagues 
examined the role of excitatory compared with inhibitory neurotransmission in mediating the 
effects of leptin on energy homeostasis (587). To do this they created transgenic mice with loss of 
leptin-signaling in glutamatergic (VGlut2; excitatory) or GABAergic (VGat; inhibitory) neurons. 
They found that predominantly inhibitory GABAergic signaling was important for mediating the 
downstream effects of leptin on energy homeostasis, while the contribution of excitatory 
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glutamatergic neurons was relatively small. GABAergic neurons that are directly responsive to 
leptin (as indicated by leptin-induced pSTAT3 immunoreactivity) were found in the ARC, DMH 
and LHA. 
While the hypothalamus has been the main area of the brain that has been studied with respect 
to the role of leptin in the regulation of energy homeostasis, other brain regions including nuclei of 
the hindbrain and components of the mesolimbic dopamine system have also been investigated 
(see figure 2). 
 
Leptin-mediated effects on energy homeostasis via the hypothalamus 
Perhaps the best known and well characterized CNS targets of leptin are the hypothalamic 
neurons involved in the modulation of energy homeostasis. Early studies indicated that in addition 
to reducing food intake, hyperglycemia and hyperinsulinemia, chronic leptin treatment in mice 
reduced hypothalamic NPY mRNA in ob/ob mice, suggesting that NPY neurons of the 
hypothalamus were key mediators of the effects of leptin on food intake and glucose homeostasis 
(539). Importantly, the effects of leptin on regulating hypothalamic NPY mRNA levels in this 
model are a direct consequence of leptin treatment and not merely a side effect of weight-loss, as 
vehicle-treated ob/ob animals which were pair-fed to the leptin-treated ob/ob group showed a 
similar degree of weight-loss with no associated reduction in hypothalamic NPY mRNA levels 
(506). Another key observation in this important study was the finding that leptin-treated ob/ob 
mice showed a greater reduction in serum glucose and insulin than pair-fed vehicle-treated ob/ob 
mice, which lost similar amounts of body weight, providing an early indication of a key role of 
leptin in regulating glucose homeostasis independent of its impact on body weight (506).  The 
ability of leptin to regulate hypothalamic NPY mRNA was also replicated in wild-type animals 
where leptin treatment can reverse fasting-induced reductions in expression of this gene (506). A 
key role for NPY in mediating the effects on leptin on energy homeostasis was reinforced by 
additional studies demonstrating that leptin receptors are localized in NPY neurons of the rodent 
brain (397) and these neurons express SOCS3 and STAT3 after peripheral administration of 
leptin (174, 234). Furthermore, genetic deletion of NPY in ob/ob mice partially reverses their 
obesity phenotype (183).  
The finding that loss of NPY-signaling attenuated but did not completely reverse the obesity 
phenotype in ob/ob mice (183) suggested there were other important downstream targets of 
leptin’s effects on energy homeostasis that remained to be discovered. Like the ob/ob mouse, the 
phenotype of the obese yellow (A
y
) mouse had been described in the 1940’s (150) but in the late 
1990’s when the mechanisms of leptin’s actions on energy homeostasis were beginning to be 
elucidated the underlying molecular basis of the obesity in this model was also undetermined. It 
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was known that genetic mutations in the A
y 
mouse and the phenotypically-related viable-yellow 
(Av
y
) mouse both resulted in ectopic over-expression of the agouti protein which was known to be 
important in regulating pigmentation in hair follicles via its action on melanocortin-1 receptors 
(MC1R) (369). As mice that lack MC1R are not obese (484) the obesity phenotype of the A
y
 
mouse could only be due to the action of agouti at an alternative receptor. Being expressed in a 
number of key hypothalamic sites important for the regulation of energy homeostasis (and other 
neuroendocrine and autonomic functions) (412) the melanocortin-4 receptor (MC4R) was a key 
candidate. In 1997 the MC4R-null mouse was generated and found to have an obesity syndrome 
highly similar to that of the A
y
 mouse, but without the associated coat color phenotype (284). 
Shortly thereafter, leptin receptors were found to be expressed on ARC POMC-neurons (the 
major source of endogenous melanocortin receptor agonists in the brain) (108) and 
administration of a synthetic antagonist for the MC3R and MC4R (SHU9119) into the brain was 
able to attenuate the ability of peripherally administered leptin to reduce food intake (510). These 
studies indicated an important role for the central melanocortin system in mediating the 
downstream effects of leptin on energy homeostasis. However, crossing A
y
 and ob/ob mouse 
strains together indicates that while central melanocortin signaling is important for mediating the 
effects of leptin, it can also exert effects on energy homeostasis (and indeed other 
neuroendocrine pathways) independent of leptin signaling (61).  
In 1997, a homologue of agouti was cloned and discovered to be a selective endogenous 
antagonist of the melanocortin receptors expressed in the brain (MC3R and MC4R) (433). Named 
AgRP, its mRNA was found to be expressed in the ARC and ME and to be down regulated in 
obese ob/ob mice but highly upregulated by fasting (233, 433, 520). Transgenic overexpression 
of AgRP under the control of the β-actin promotor resulted in a similar phenotype to the mice with 
transgenic overexpression of Agouti, however, without the alterations in pigmentation (433). A 
single injection of AgRP directly into the brain robustly increases food intake (169) an effect that 
persists for several days (232). Soon after its discovery, AgRP was shown to co-localize with NPY 
in the ARC in neurons with close proximity to POMC neurons (233) and suggested that a 
presence of a critical leptin-sensitive neuronal circuit regulating energy homeostasis within the 
hypothalamus. ARC POMC neurons have also been shown to co-express cocaine- and 
amphetamine-regulated transcript (CART), another neuropeptide which reduces food intake and 
whose expression is regulated by nutritional status and leptin (330). The leptin-sensitive 
melanocortin circuit in the ARC made up of anorexigenic POMC/CART neurons and orexigenic 
NPY/AgRP neurons, which inhibit and stimulate food intake respectively, plays a pivotal role in 
energy homeostasis via MC4R expressed at downstream sites, including the PVH, has been 
extensively studied and recently comprehensively reviewed elsewhere (547) (summarized in inset 
box of figure 2). This central melanocortin circuit has also been shown to be critical for mediating 
the effects of other key hormones involved in regulating energy homeostasis including 
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adiponectin (464), ghrelin (573, 593) and insulin (45), and as such the modulatory activation of 
leptin on this circuit can in turn modulate the efficacy of these key metabolic hormones (113, 256, 
564). 
The importance of ARC leptin signaling in the regulation of energy homeostasis is indicated by a 
study showing that introduction of functional leptin receptors in the ARC of Koletsky rats, which 
have defective leptin-signaling, using an adenoviral mediated gene delivery approach attenuates 
the obesity phenotype in this model (409). In genetically modified mice which are obese due to 
the presence of a transcriptional blocker inhibiting leptin receptor expression, site-specific 
reactivation of leptin receptor expression in ARC neurons alone is sufficient to improve the 
obesity, hyperinsulinemia, hyperglycemia and hypoactivity (129). Modulations in energy 
homeostasis are also seen in a number of other studies in mice looking at modulating leptin-
signaling specifically in POMC (24, 152, 257, 307, 459, 581) and AgRP neurons (581). 
Collectively these studies reveal subtle differences in the role of different elements of ARC leptin 
signaling in regulating body weight and glucose homeostasis, but importantly demonstrate that 
the ARC is not the sole site mediating the effects of leptin on energy balance. 
Detailed mapping studies indicate that while the ARC is one of the hypothalamic sites with the 
highest level of cell bodies expressing leptin receptor significant numbers were also found in the 
ventral premammillary nucleus (vPMN) and the DMH, while neuronal projections of leptin 
receptor expressing neurons were enriched in the PVH, anteroventral periventricular nucleus and 
the central nucleus of the amygdala (449). These findings are supported by studies mapping of 
pSTAT3 immunoreactivity after peripheral leptin-treatment (413). The widespread expression of 
leptin receptors/leptin-responsive neurons in different hypothalamic nuclei highlights that the 
modulatory actions of leptin on energy homeostasis circuits are complex and diverse and extend 
far beyond the ARC (417). 
The LHA is important for regulating feeding behavior, wakefulness and arousal (59). Importantly, 
the LHA is also critical for mediating reward behavior and is a key gateway between the 
hypothalamus and the mesolimbic dopamine system (151, 246, 305). Neurons of the LHA 
express leptin receptors (180, 352) and are directly responsive to leptin as indicated by leptin-
induced expression on pSTAT3 immunoreactivity and changes in electrical activity (352). Indeed, 
different populations of LHA neurons were either depolarized or hyperpolarized by leptin 
suggesting that leptin may exert differential effects via the modulation of neuronal activity in this 
brain region. In addition to direct regulation, the LHA can also be indirectly regulated by leptin via 
ARC NPY and POMC neurons which project to the LHA (174, 177). Direct administration of leptin 
into the LHA decreases food intake and body weight in rats (352) supporting a role for the LHA in 
mediating the homeostatic effects of leptin. This is further supported by data indicating that 
disruption of leptin-signaling in the LHA increases food intake and body weight (139).  
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Within the LHA leptin receptor neurons are GABAergic (352, 587) and a subpopulation(s) of 
these also express the neuropeptides neurotensin (353) and galanin (339). Interestingly, despite 
their known role in regulating energy homeostasis (497, 518) - both are implicated in stimulating 
feeding - neither orexin nor melanin concentrating hormone (MCH) neurons in the LHA contain 
leptin receptors (352). However, leptin can exert an indirect inhibitory effect on LHA orexin (but 
not MCH) neurons via adjacent neurotensin (216, 368) and galanin neurons (338). Genetic-
deletion of leptin receptors from neurotensin neurons results in animals with early-onset obesity 
associated with elevated food intake and reduced locomotor activity (353). In contrast, leptin 
receptor deletion from galanin neurons results in late onset obesity and an increased preference 
for sucrose over fat (338). Although galanin and neurotensin extensively colocalize in the LHA 
(339), the differential effects of loss of leptin-signaling in galanin compared with neurotensin 
neurons may potentially be explained by the fact that while both neuronal populations innervate 
orexin neurons within the LHA, galanin neurons in this region project to the locus coeruleus (338) 
and neurotensin neurons project to the VTA (353). The differences in phenotype between the two 
models may also be explained by the fact that both neurotensin and galanin are expressed in 
neurons at sites outside of the LHA (321, 525). Myers and colleagues have proposed a model in 
which leptin receptor expressing neurons in the LHA tonically inhibit local orexin neurons and that 
reductions in leptin-signaling, associated with negative energy balance e.g. fasting or starvation, 
remove this inhibition leading to increased activity of orexin neurons resulting in increased food 
intake, arousal, and locomotor activity (216).  
The DMH is another key hypothalamic site mediating the effects of leptin on energy homeostasis. 
Indeed, diet-induced obesity in rodents is associated with induction of NPY expression in this 
region, which is not evident under normal weight animals (227). These diet-induced obesity 
associated DMH NPY neurons coexpress CART, and leptin directly induces depolarization and 
increased firing activity in these cells (348) indicating a potential role for leptin in regulating their 
activity. Leptin-action in the DMH has been shown in a series of independent studies to be critical 
for the regulation of energy expenditure/thermogenesis. Leptin-deficient ob/ob mice have 
profound deficits in their ability to regulate brown adipose tissue (BAT) activity and adjust to cold 
temperatures (260, 570, 571) indicating a key role for leptin in regulating this key physiological 
adaptation. Furthermore, the ability of leptin to reduce body weight in mice is partially dependent 
on thermogenesis in BAT (126).  
A central circuit encompassing projections between the median preoptic area (mPOA), DMH and 
rostral raphe pallidus (rPA) (84, 623) regulates sympathetic output to BAT during cold exposure. 
Retrograde labeling studies in mice have demonstrated that a subpopulation leptin receptor 
expressing neurons in the DMH project to BAT and are activated (as assessed by expression of 
c-FOS immunoreactivity) by cold-exposure (636). These anatomical findings were supported by 
physiological studies published around the same time by an independent group which indicate 
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that intra-DMH administration of a leptin receptor antagonist in mice was sufficient to attenuate 
the thermogenic effect of peripherally administered leptin (182). Intra-DMH leptin administration 
can also reverse the low body temperature (hypothermia) that is a physiological characteristic of 
leptin-deficient ob/ob mice (483). Interestingly, the hyperthermic effect of leptin is intact in diet-
induced obese mice, which is in contrast to leptin’s effects on food intake which are attenuated by 
obesity (182). 
Activation of DMH leptin receptor cells using Designer Receptors Exclusively Activated by 
Designer Drugs (DREADDs) induces weight-loss associated with increased energy expenditure 
(BAT thermogenesis and locomotor activity) but not changes in food intake (483). The same 
study indicates that virally mediated genetic deletion of leptin receptors from DMH neurons in 
mice produces the opposite effect, namely increased body weight associated with reduced 
energy expenditure and locomotor activity (483). A complementary study by the same group also 
demonstrated an important role for leptin receptors in the mPOA in mediating body temperature, 
further reinforcing a key role for leptin in modulating the tone of the central circuit regulating 
thermogenesis (625). Within the DMH prolactin-releasing peptide (PrRP) neurons are responsive 
to leptin and deletion of leptin receptors from these cells attenuates the thermogenic effects of 
leptin indicating that DMH PrRP neurons are key mediators of leptin’s effect on thermogenesis 
(155). 
 The VMH has long been known to be a key site in the regulation of energy homeostasis. Early 
studies indicated that lesioning the VMH region in rodents leads to profound obesity (254) and 
furthermore, mice which lack the transcription factor steroidogenic factor-1 (SF-1) have defective 
VMH development and are obese (378). The VMH has populations of glucose-sensing neurons 
(for review see (492)). Critically, VMH neurons also expresses leptin receptors (180) and are 
directly responsive to leptin, as indicated by the expression of  nuclear localization of STAT3 after 
leptin treatment  (275). Direct injection of leptin in to the VMH is sufficient to reduce food intake 
(290, 501) and stimulate sympathetic nervous system activation in rodents (243, 502). 
Interestingly, pregnancy is associated with a reduction in leptin receptor mRNA and a 
concomitant reduction in leptin-induced pSTAT3 in the VMH but not the ARC, suggesting that the 
VMH may be a critical site mediating pregnancy-induced leptin-resistance (336). 
Neurons in the medial VMH send excitatory inputs to ARC POMC neurons (542), providing 
evidence for a functional regulatory interaction between these two leptin-sensitive areas. Loss of 
leptin receptor signaling in SF-1 neurons of the VMH results in obesity and impaired glucose 
tolerance on standard chow and also enhanced weight gain on a high-fat diet (52, 149). In 
support of a potential role for VMH leptin signaling in sympathetic nervous system activation, 
mice with loss of leptin receptor signaling in SF-1 neurons display a defect in diet-induced 
thermogenesis (149). Activation of PI3K signaling is one of the pathways downstream of leptin 
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receptor activation (423, 638). PI3K signaling in VMH SF-1 neurons leads to enhanced diet-
induced obesity and a defect in diet-induced thermogenesis, suggesting the PI3K may be one of 
the key signaling pathways mediating the effects of leptin in VMH neurons (613). Furthermore, 
the effect of VMH leptin signaling on tissue glucose utilization and insulin-sensitivity appear to be 
mediated via ERK signaling (565). Enhancing leptin signaling in VMH SF-1 neurons by specific 
deletion of SOCS3 increased the efficacy of leptin in reducing food intake and also resulted in 
improved glucose homeostasis in both standard chow and high-fat fed mice (634). Preventing 
PTP1B mediated inhibition of leptin signaling in VMH SF-1 neurons (SF-1 PTP1B null mice) also 
enhances leptin-sensitivity but surprisingly resulted in increased body weight in high-fat fed 
female mice, which was associated with reduced energy expenditure and sympathetic nervous 
system activity (111). As PTP1B also regulates insulin signaling, it is has been proposed that 
enhanced insulin signaling in the SF-1 PTP1B null mice counteract the effects of improved leptin-
sensitivity in these animals when exposed to a high-fat obesogenic diet (111).  The 
neurochemical identity of leptin responsive neurons in the VMH remains to be fully determined, 
but candidates include pituitary adenylate cyclase-activating polypeptide (PACAP) (248) and 
dynorphin (175).  
Within the hypothalamus multiple distinct nuclei are sensitive to leptin and have been implicated 
in mediating the effects of the adipokine on energy homeostasis. While some overlapping actions/ 
redundancy exist it is likely that we have yet to uncover the true integrative and coordinated 
action of these site in the regulation of this complex physiologic process. 
 
Extra-hypothalamic effects of leptin on energy homeostasis 
While the hypothalamic effects of leptin in regulating energy homeostasis have been the most 
extensively studied (see preceding section), deletion of leptin receptors from various 
hypothalamic neuronal populations (described above (24, 52, 149, 152, 257, 307, 338, 353, 459, 
581)) does not fully recapitulate the metabolic phenotype of the animals with congenital leptin-
signaling defects (122, 211, 285, 570, 571). This indicates that leptin signaling in extra-
hypothalamic areas is also critical for the normal regulation of energy homeostasis. 
Leptin-mediated effects on energy homeostasis via the hindbrain 
In animal models, leptin receptor expression has been reported in a number of hindbrain sites 
relevant to the regulation of energy homeostasis including the area postrema, nucleus of the 
solitary tract (NTS), dorsomotor nucleus of the vagus (DMX), lateral parabrachial nucleus (lPB), 
and ventrolateral medulla  (VLM) (225, 399, 400). However, variation in distribution and 
abundance has been reported between mammalian species (399, 400). Early studies indicated 
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that administration of leptin in rodents induces c-FOS immunoreactivity in the NTS and  lPB in the 
brainstem (179); yet, subsequent studies reported low levels of activation in the NTS (175, 591), 
suggestive of a failure of leptin to activate neurons in this region. As c-FOS is thought to 
principally be a marker of neuronal activation, the failure of leptin to induce c-FOS in the NTS 
may be explained by the finding that leptin has been found to inhibit excitability of NTS neurons 
(604). Mapping of leptin-induced expression of phosphorylated STAT3 confirms that the NTS, 
DMX and lPB are direct targets for the action of leptin (79, 178, 209, 225, 266, 281).  
Neurochemical characterization indicates that cholecystokinin (CCK) neurons in the lPB and NTS 
are leptin-responsive (175, 209). Additionally, in the NTS preproglucagon (a precursor for 
glucagon like peptide-1 [GLP-1]) and POMC neurons are direct targets for leptin (178, 209, 281), 
while cholinergic neurons are a target of leptin in the DMX (79).  
The functional significance of these anatomical studies has been verified by numerous 
independent groups. Administration of leptin into the fourth ventricle or dorsal vagal complex 
(DVC; a region of the brainstem encompassing the NTS, area postrema and DMX) reduces 24 h 
food intake and induces weight-loss over the same period (225). In a subsequent study the viral-
mediated knock-down of leptin receptor expression in the DVC in rats caused modest but chronic 
hyperphagia leading to body weight gain (250) indicating a role for endogenous leptin signaling in 
the homeostatic regulation of food intake. Loss of leptin receptors from hindbrain 
preproglucagon/GLP-1 neurons in mice led to a similar phenotype of modest hyperphagia and 
weight gain (509) , although phenotypic differences were seen in the animals between the two 
studies which the authors propose may be related to differences in brain stem expression of 
leptin receptors in mice and rats (282).  
One of the mechanisms by which brainstem leptin-signaling has been proposed to modulate 
energy homeostasis is via modulation of gut-brain communication. An early study indicated that 
injection of leptin into the fourth ventricle was sufficient to inhibit gastric emptying (526) 
supporting a role for leptin in modulating gastrointestinal (GI) function, likely via modulation of 
vagal efferent tone. This early work was followed on by subsequent studies indicating that 
peripheral leptin treatment enhanced NTS neuron activity in response to gastric distention (505) 
and nutrient preloading (181), thus providing a neurophysiologic mechanism for how leptin may 
act to reduce meal size.  
Related studies have demonstrated that leptin is able to impact food intake via modulation of the 
action of gut released peptides at hindbrain sites. CCK released from the GI tract acts as a satiety 
factor reducing meal size via its action on receptors located on vagal afferents which are relayed 
to the DVC in the brainstem and also forward on to higher centers regulating food intake (154). 
Multiple independent groups have demonstrated that in rodents the injection of sub-threshold 
doses of leptin and CCK, which alone do not influence feeding behavior, can produce reductions 
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in food intake indicative of a synergistic action of the two peptides (10, 35, 390, 603). This effect 
was seen when leptin was administered peripherally (10, 35) or into brain via cerebroventricular 
injection (390, 603). The inter-relationship between leptin- and CCK-signaling is further 
strengthened by the finding that absence of intact leptin signaling in Koleysky (408) or Zucker 
(401) rats is associated with increased meal-size and relative insensitivity to the effects of CCK 
on food intake, although interpretation of these findings may be complicated by the profound 
obesity in these models that likely impacts numerous parameters. However, the importance of 
leptin in modulating the actions of CCK on food intake in a physiological context are further 
supported by the data indicating that fasting-induced reductions in circulating leptin also impair 
the ability of CCK to reduce food intake, an effect that can be reversed by restoration of leptin 
levels by exogenous administration of leptin (393). Leptin receptors in the NTS are critical for 
mediating the effects of CCK on food intake as adenoviral mediated knockdown of leptin 
receptors in this brain region attenuates the satiating effect of exogenously administered CCK 
and also leads to an increased meal size, indicative of a disruption of the normal satiety pathways 
(250).  
In addition to NTS leptin-signaling forebrain sites have also been implicated as being important in 
mediating the synergetic interaction between leptin and CCK. Co-administration of leptin and 
CCK leads to an amplification of neuronal activation in the PVH, as assessed by c-FOS 
immunoreactivity, compared with that seen following either peptide alone, suggesting that the 
PVH may be an important site of functional convergence of both peptides (35, 181). Indeed, 
surgical transection of the connectivity between forebrain and hindbrain in rats prevented the 
inhibition of food intake associated with co-administration of leptin and CCK, indicating that 
connectivity between the two areas is critical for mediating the synergetic action of these two 
peptides (10). Descending oxytocin pathways from the PVH to the NTS have been implicated as 
potential key mediators (57). Interestingly, in Koletsky rats restoration of leptin-signaling in the 
ARC, a brain region with direct connectivity to the PVH, using viral-mediated gene delivery was 
sufficient to reduce average meal-size to that seen in wild-type animals and also restore 
sensitivity to the satiating effects of exogenously administered CCK (408). Together, these data 
suggest that hypothalamic leptin-signaling can modulate the activity of CCK via descending 
neuronal pathways from the PVH to the NTS. Interestingly, a recent study has demonstrated that 
CCK-neurons of the NTS, that are known to be leptin responsive (209), project to the PVH and 
play an important role in regulating satiety (133). 
In common with CCK, leptin has also been shown to act synergistically with GLP-1 to reduce food 
intake; indeed the interaction between GLP-1 and leptin in the regulation of energy homeostasis 
bears a lot of similarities to the interaction with CCK described above. GLP-1 like CCK is a 
peptide released from the GI tract that has been shown to mediate satiety and is also expressed 
in neurons of the NTS of the brain stem (568). Peripherally secreted GLP-1 is also an incretin 
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hormone. It is not clear whether peripherally derived GLP-1 enters the brain and/or whether the 
interaction between leptin and GLP-1 signaling in the CNS is largely mediated downstream of 
CNS derived GLP-1 (568).  As described above, leptin receptors are found on  GLP-1 neurons in 
the NTS (218) and are directly responsive to leptin-treatment in mice as indicated by expression 
of pSTAT3 immunoreactivity (209, 281). Electrophysiologic studies indicate that GLP-
1/preproglucagon neurons of the NTS are depolarized by leptin and receive direct input from 
vagal afferent fibers (261). Intracerebroventricular administration of a GLP-1 antagonist [extendin 
9-39] at a dose that had no effect when administered alone, is sufficient to attenuate the effect of 
leptin on food intake (218, 639), implicating GLP-1 signaling in mediating some of the 
downstream effects of leptin on food intake. Furthermore, co-administration of leptin and a GLP-1 
agonist [exendin-4] into the fourth cerebroventricle in rats had an additive inhibitory effect on food 
intake.  In rats, peripheral leptin administration can attenuate fasting-induced reductions in NTS 
GLP-1 mRNA (281) an effect that is not seen in mice, indicating that there may be important 
differences between the two species. NTS GLP-1 neurons send projections to the hypothalamus 
as well as a number of other brain sites (340).  As with CCK, intact hypothalamus-brainstem 
connectivity appears to be required for the interaction between leptin and GLP-1 signaling in the 
regulation of energy homeostasis, as the additive effect on food intake is attenuated in midbrain 
transected rats (11). Loss of leptin receptors from GLP-1 neurons in the NTS is sufficient to 
impact food intake and induce a modest increase in body weight in animals fed standard 
laboratory chow indicating that endogenous GLP-1 neurons are important downstream mediators 
of endogenous leptin signaling (509). These animals are, however, capable of reducing their food 
intake and body weight in response to exogenous peripheral leptin infusion over the course of a 
week, indicating that in this context leptin receptors on GLP-1 neurons are not required for the 
effect on food intake and body weight, likely due to a compensation by other leptin activated 
pathways. 
In addition to the caudal brainstem nuclei (NTS, AP, VLM and DMX) another direct target of leptin 
in the hindbrain is the lPB (79, 178, 209, 225, 266, 281). The parabrachial nucleus (PBN) is a key 
intermediary site linking the hypothalamus to the caudal brainstem including the NTS and VLM 
(500). Within the PBN, leptin receptors are expressed in CCK neurons which project to the VMH 
(194). Leptin receptor expressing neurons in the PBN are inhibited by leptin but activated by low 
glucose levels indicating that they may be a key regulatory node for low-glucose sensing linking 
the hypothalamus and brainstem (194). Deletion of leptin receptors from CCK neurons resulted in 
mice with an exaggerated counter-regulatory response (CRR) to low-glucose characterized by a 
reduced glucose infusion rate in a hypoglycemic clamp (194). The same study nicely 
demonstrated using chemogenetic technologies (DREADDs) that inhibition of the activity 
specifically of PBN leptin receptor containing neurons blunted the CRR while activation of these 
neurons enhanced it, in a process that could be inhibited by the CCK-receptor antagonist 
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proglumide. While mice with deletion of leptin receptors from all CCK neurons including those 
found in the PBN show normal food intake and body weight, an independent study demonstrated 
that direct injection of leptin into the PBN reduces food intake and meal size in rats leading to a 
reduction in body weight (13). This suggests that the effect of intra-PBN leptin on food intake is 
mediated by neurons in the PBN that do not contain CCK or alternatively, that other pathways 
adapt to maintain normal energy homeostasis in mice with leptin receptors deleted from their 
CCK neurons. 
  
Role for non-neuronal targets of leptin in the regulation of energy homeostasis 
Within the CNS the majority of work examining the role of leptin in regulating energy homeostasis 
has focused on neuronal signaling; however recent work has begun to explore the contribution of 
non-neuronal cells as targets for leptin’s actions, in particular the potential role of astrocytes. 
Leptin receptors are expressed in astrocytes (110, 271, 272, 442). Indeed, astrocytes have been 
shown to be directly responsive to leptin as indicated by increased translocation of STAT5 to the 
nucleus of astrocytes following systemic leptin treatment in vivo in rats (415). Additionally, studies 
show that leptin treatment can induce both pSTAT3 and pSTAT5 in astrocytes in vitro, with 
pSTAT5 showing more pronounced regulation (60) indicating that it may be the predominant 
signaling pathway downstream of leptin receptor activation in astrocytes; however, further work 
needs to be done in this area. In vitro, leptin induces an increase in intracellular calcium in 
astrocytes, providing further evidence of a functional effect of leptin on downstream signaling in 
astrocytes (272). 
In obese animal models, both monogenic and diet-induced, leptin receptor expression is 
upregulated in hypothalamic astrocytes, suggestive of a potential role of astrocytic leptin-signaling 
in the regulation of energy homeostasis (272, 442). This expression data is supported by 
mechanistic studies indicating that leptin treatment regulates both the structure and function of 
hypothalamic astrocytes; including levels of hypothalamic glial-fibrillary acidic protein (GFAP) and 
vimentin, key structural proteins (207), as well as the expression of glucose and glutamate 
transporters found in astrocytes (202). Conditional deletion of leptin receptors from GFAP-
expressing astrocytes in adult mice reduces astrocytic coverage of melanocortin neurons (POMC 
and AgRP) in the ARC resulting in an increase in synapse number and a change in the 
neurophysiological activity of these neuronal populations (310). While there were no notable 
differences in feeding behavior in these animals under normal husbandry conditions (freely 
available standard chow), the animals’ demonstrated altered physiological responses when 
experimentally challenged. Conditional deletion of leptin receptors from GFAP-expressing 
astrocytes in mice resulted in an enhanced response to manipulations that typically increase food 
intake, fasting or ghrelin treatment, and attenuation of the ability of leptin to reduce food intake 
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(310). Together these data point to a role for leptin in regulating the astrocytic modulation of 
synaptic activity in ARC melanocortin neurons. The importance of astrocytes in mediating the 
effects of leptin on energy homeostasis was supported by a subsequent study demonstrating that 
chemogenetic activation of astrocytes using DREADDs enhanced the reduction in food intake 
associated with leptin-treatment, while inhibition of astrocytes attenuated it (618). Of note, germ-
line deletion of leptin receptors from GFAP-expressing cells does not lead to any overt changes in 
body weight or feeding behavior on standard chow, but a modest and complex difference in their 
response to high-fat feeding that requires further study (293). 
 
Effects of leptin on the modulation of CNS reward pathways 
In addition to increasing food-seeking behavior, negative energy balance associated with food 
restriction/fasting increases other motivated behaviors including drug-seeking and rewarding 
brain self-stimulation via electrodes implanted into the brain (435). As such, food-restriction is 
often used as an experimental context in neurobehavioral studies in rodents as a motivational 
tool. Early functional in vivo studies indicated that intracerebroventricular treatment with leptin can 
attenuate the ability of food-restriction to increase rewarding brain self-stimulation, via electrodes 
implanted in the LHA, providing evidence for a role of leptin in modulating reward pathways (206). 
The dopaminergic reward pathways are critical for the regulation of motivated behaviors including 
food-seeking (606). Leptin receptors are expressed on dopaminergic (191, 264) and GABAergic 
neurons of the VTA which project to the nucleus accumbens (205) suggestive of a role of leptin in 
modulating the critical mesoaccumbens dopamine pathway. Ex vivo, leptin decreases the 
frequency of excitatory postsynaptic currents in VTA dopaminergic neurons, providing a 
neurophysiological evidence for a role of leptin in modulating the activity of this pathway (563). 
This is supported by studies which demonstrate that absence of leptin-signaling in leptin deficient 
ob/ob mice is associated with reduced levels of tyrosine hydroxylase, the rate limiting enzyme in 
dopamine synthesis, in the VTA and a deficit in amphetamine-induced motivated behavior (205), 
both of which can be reversed by systemic leptin treatment. Leptin acting directly in reward 
centers of the brain has also been shown to modulate feeding.  Administration of leptin directly 
into the VTA reduces food intake in rodents while knock-down of leptin receptors in this region 
increases food intake and preference for palatable foods (sucrose and high-fat) (264). The effect 
of intra-VTA administered leptin on food intake appears to be dependent on JAK2 signaling but 
not PI3K or mechanistic target of rapomycin (mTOR), which is in contrast to the effects of intra-
hypothalamic leptin (407).   
In addition to mediating important aspects of the leptin effect on food intake, VTA leptin signaling 
is also important for energy expenditure as loss of STAT3 signaling in dopamine neurons is 
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associated with an increase in the rewarding effect of voluntary activity (running) in mice (189), an 
effect that can be reverse by intra-VTA administration of leptin. Leptin receptor expressing 
neurotensin neurons of the LHA innervate the VTA and intra-LHA administration of leptin into 
leptin deficient ob/ob mice was sufficient to increase VTA tyrosine hydroxylase gene expression 
and nucleus accumbens dopamine levels, indicating a functional anatomic link between LHA and 
the mesoaccumbens dopamine system (352, 353). Like the hypothalamic nuclei, the VTA 
neurons also show cellular leptin resistance in response to diet-induced obesity (387). 
 
Leptin in the modulation of other neuroendocrine axes 
 
Reproduction 
Reproduction is energetically demanding, particularly for female animals. As such, having 
sufficient energy reserves in the form of stored body fat is essential for the health of the mother 
and the offspring. Circulating leptin levels play a key role in communicating information on body 
fat stores to the CNS, with a drop in circulating leptin levels being a key mediator of the 
neuroendocrine deficits triggered by the reduction in energy availability associated with fasting 
(8). Leptin has been shown in numerous studies to have a key role in modulating multiple aspects 
of reproductive function from puberty to lactation (98).  
Before the cloning of leptin it was known that both male and female obese ob/ob mice had severe 
reproductive deficits with the homozygous female animals being sterile and the male animals only 
capable of reproducing when their excess body weight was curtailed by food restriction (127).  
Detailed characterization of these animals revealed an absence of ovulation due to reduced 
levels of reproductive hormones associated with dysfunction at the hypothalamic-pituitary level 
(40, 493-495, 549); ovaries from female ob/ob mice were functional when transplanted into lean 
mice (279). The reduced levels of reproductive hormones in ob/ob mice cause immaturity/atrophy 
of the reproductive organs (550). Breeding of homozygous ob/ob animals is typically achieved 
through pairing heterozygous ob/+ animals. 
After the cloning of the Ob gene and identification of the hormone leptin in 1994, early studies 
explored whether leptin replacement in ob/ob animals was sufficient to reverse the reproductive 
deficits. Continuous peripheral leptin-treatment in adult female ob/ob mice was able to restore the 
ability of the animals to become pregnant, deliver and nurse healthy pups (99). While the leptin-
treatment in female ob/ob mice caused a reduction in body mass, weight-loss in control ob/ob 
mice caused by food restriction alone was not sufficient to restore reproductive capacity indicating 
that the absence of leptin signaling and not just obesity was the principal cause of sterility in the 
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mice. Continuous leptin treatment was required to restore fertility in ob/ob mice as subsequent 
withdrawal of treatment post-partum prevented subsequent pregnancies (99). A complementary 
study of Barash and colleagues, published in the same year, indicated that two-weeks’ of 
peripheral leptin treatment in both male and female ob/ob mice caused an increase in gonad 
weight, and began to normalize some of the notable histologic differences in the seminal vessels 
(males), ovaries and uterus (females), compared with control animals. Serum levels of key 
reproductive hormones were also regulated in ob/ob mice by leptin treatment; females showed 
elevated serum luteinizing hormone (LH) and males elevated serum follicle–stimulating hormone 
(FSH) (33). As with the study of Chehab and colleagues, these effects were found to be 
independent of leptin’s effect on body-weight. Together these early studies pointed to a critical 
role for leptin in the control of the reproductive system. Intriguingly, the genetic background of the 
ob/ob mice is a critical factor determining the severity of the loss of leptin signaling on 
reproductive function, with ob/ob mice on a C57BL6 background being largely sterile while 
animals which carry with the same mutation of the BALB/cJ background are capable of 
reproducing despite profound obesity (184) suggesting the existence a strain dependent genetic 
modifiers of leptin’s effect on reproduction. 
In addition to animal models, intact leptin signaling has also been shown to be critical for 
reproductive function in humans. Although rare in humans, in agreement with the data from mice, 
genetic defects in the ob gene cause severe obesity and individuals do not undergo puberty 
unless treated with leptin (186, 404). However, leptin has also been shown to be critical for 
reproductive function in humans without genetic alterations in leptin signaling. Amenorrhea is 
seen in female patients with very low leptin levels caused by the presence of low body fat 
including athletes (341), patients with anorexia nervosa (252, 324) or lipodystrophy (583). This 
has been shown to be reversible by leptin treatment in athletes and others with hypothalamic 
amenorrhea (114, 599). 
 
Puberty 
Body fat level is associated with the onset of puberty with low levels such as those seen in female 
athletes being associated with delayed onset (197) while high levels of body fat associated with 
obesity are linked to early onset (12, 140). In boys and girls increased serum leptin levels have 
been shown to be associated with the onset of puberty (117, 208, 380). Studies in wild-type 
female mice indicate that peripheral administration of leptin causes earlier onset of puberty and 
maturation of the reproductive tract (6, 100); however other studies suggest that in the rodent the 
role of leptin is more permissive, necessary for the onset of puberty but not sufficient to trigger it 
(109).  
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CNS pathways mediating leptin’s effects on the reproductive axis 
Pulsatile gonadotrophin-releasing hormone (GnRH) secretion and the subsequent surge of LH 
prior to ovulation is critical for reproduction in female mammals. Leptin receptors are expressed in 
the pituitary gland (168, 630) and also hypothalamic neuroendocrine neurons (table 2) which are 
key components of the reproductive axes. Loss of leptin receptors specifically in neurons is 
sufficient to reduce plasma estradiol levels in female mice indicating a key role of centrally acting 
leptin in mediating female sex hormone secretion (120). Interestingly, in the same study, plasma 
testosterone levels were unchanged by neuronal leptin receptor deletion, suggesting sexual 
dimorphism in how leptin impacts reproduction. In a complementary study, reintroduction of 
functional leptin receptors into neurons in db/db mice (which have defective leptin signaling) is 
sufficient to restore fertility in both male and female animals (490) reinforcing the critical role of 
neuronal leptin signaling for fertility. 
In male and female rats, sheep, cows and rhesus monkeys peripheral leptin treatment is sufficient 
to reverse the fasting-induced reduction in pulsatile LH secretion (193, 322, 373, 418, 596) 
providing evidence for a role of leptin in the nutritional regulation of reproductive hormone 
secretion across multiple species. Administration of a leptin anti-serum also decreases LH 
pulsatility in normally fed female rats providing further evidence of a role of leptin in the 
modulation of LH secretion in the absence of a nutritional stress (90). The effects of leptin on LH 
secretion can be prevented by antagonism of central MC4R (596) indicating a potential role of the 
central melanocortin system in mediating the effects of leptin on secretion of reproductive 
hormones. The absence of leptin receptor expression on GnRH neurons (193) indicates an 
indirect effect of leptin in modulating this pathway. An indirect effect of leptin in modulating GnRH 
neurons was supported by a robust study in mice which demonstrated that leptin administration 
into the brain failed to induce STAT3 signaling in GnRH neurons and genetic deletion of leptin 
receptors specifically from GnRH neurons in mice had no impact on fertility (467).  
A number of CNS pathways have been implicated in mediating the effect of leptin on 
reproduction. It has been argued that the redundancy within this pathway is understandable from 
an evolutionary context given the importance of reproduction for survival of a species (98). The 
kisspeptin pathway, peptides encoded by the Kiss1 gene acting via the Kiss1-receptor/GPR54, is 
a key regulator of puberty and reproduction in humans and rodents (142, 513) acting via 
modulation of GnRH neurons. Kiss-1 and GPR54 are nutritionally regulated showing a reduction 
in response to calorie restriction (421) and obesity associated with a high-fat diet or leptin-
deficiency in ob/ob mice (188); all states in which leptin signaling is reduced. Leptin 
administration in leptin-deficient ob/ob mice increases Kiss-1 gene expression and induces 
sexual maturation (527). These findings led to the hypothesis that the kisspeptin pathway may be 
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a key functional link between leptin and the regulation of the reproductive axis. However, in 
common with GnRH neurons, Kiss-1 neurons do not appear to be directly activated by leptin 
(188, 421). There is also conflicting evidence as to whether ARC Kiss-1 neurons express leptin 
receptors, with some studies suggesting up to 40% colocalization (527) and others indicating that 
only a very limited number of kisspeptin neurons (<6% in the ARC and none in the anteroventral 
periventricular nucleus) express leptin receptors (311). Kiss1 expression in the brain is increased 
during pubertal development (512). A detailed analysis in the change in Kiss-1 and leptin receptor 
expression over time (94) indicates that in prepubertal female mice there are low levels of leptin 
receptor expression in Kiss-1 neurons and accordingly at this age few Kiss-1 neurons are 
activated (as assessed by pSTAT3, c-FOS or pSTAT5 immunoreactivity) by leptin treatment. 
After sexual maturation 10-15% of ARC Kiss-1 neurons expressed leptin receptors. This 
anatomic evidence is supported by genetic studies in mice that demonstrate the deletion of leptin 
receptors from hypothalamic Kiss-1 neurons has no impact on puberty (157). Furthermore, re-
expression of endogenous leptin receptors in Kiss-1 neurons of leptin receptor null animals using 
cre-mediated removal of a transcriptional blocking cassette also failed to restore normal 
reproductive function to the leptin receptor null animals (94). Together these studies indicate that 
the kisspeptin pathway is not directly mediating the effects of leptin signaling on the onset of 
puberty. But an indirect/downstream role of kisspeptin in mediating leptin’s effects on 
reproduction and the potential role of leptin in direct modulation of Kiss-1 neurons in adult animals 
has not yet been clarified. 
The central melanocortin system has also been implicated in mediating leptin’s effects on 
reproduction. Melanocortin neurons of the ARC, both POMC and AgRP, express leptin receptors 
(108, 397) and have been shown to innervate both GnRH and Kisspeptin neurons (432, 516, 
607). A subpopulation of Kiss-1 neurons of the mPOA and ARC both express MC4R (516). These 
data provide a potential anatomical basis for a role for the central melanocortin system in 
mediating the effects of leptin on reproduction. Indeed, pharmacologic studies indicate that 
inhibiting MC4R attenuates leptin’s ability to induce LH release in fasted female rats (596). 
However, others have shown that while antagonism of central melanocortin receptors 
(MC3R/MC4R) using SHU9119 attenuates leptin’s ability to reduce food intake in ob/ob mice, it 
does not prevent leptin induced stimulation of reproductive function in these animals (616). While 
leptin receptors in POMC or AgRP neurons are not necessary for the onset of puberty and fertility 
in mice (283, 453), loss of AgRP signaling or heterozygosity of MC4R is sufficient to restore 
reproductive capacity (onset of puberty, fertility and lactation) in female db/db mice without any 
significant changes in body weight (288). Together these data suggest a complex interaction 
between the leptin and melanocortin systems in the regulation of reproductive function, the study 
of which may be complicated by redundancy in the system and developmental compensation in 
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knockout mouse models. Future studies utilizing inducible transgenic models may help to provide 
more clarity. 
Genetic deletion of leptin receptors from GABAergic but not glutamatergic neurons (384) in 
female mice leads to reproductive deficits characterized by a disrupted estrous cycle and reduced 
ovarian and uterine weight. This suggests an important role for inhibitory GABAergic tone in 
mediating leptin’s effects on reproduction. Kiss-1 neurons receive GABAergic inputs which are 
regulated by both time of day and estradiol (144). GABAergic signaling has also been shown to 
regulate GnRH neuron activity (595). This suggests that a leptinGABAKisspeptin/GnRH 
pathway may be one mechanism by which leptin may be able to indirectly modulate the 
reproductive axis. Critically, AgRP neurons in the ARC are GABAergic, whereas POMC neurons 
are both GABAergic and glutamatergic (607) providing a functional anatomical link between the 
leptin and melanocortin systems that may provide further insights into how these systems interact 
in the regulation of reproduction. 
The hypothalamic ventral premammillary nucleus (PMv) has emerged as a key site mediating the 
effects of leptin on the reproductive axis. Anatomical tracing studies in mice reveal that PMv 
neurons, including those known to express leptin receptors, directly innervate GnRH neurons 
(157, 288, 355) and lesioning of the PMv in ob/ob mice attenuates the ability of exogenous leptin 
treatment to induce puberty in these animals (157). Reintroduction of leptin receptors into the 
PMv of leptin receptor null mice was sufficient to induce puberty and positively impact fertility in 
the absence of any notable effect on the body weight of the animals, which remained obese 
(157). These studies revealed an anatomical dissociation between the brain regions mediating 
the effects of leptin on reproduction and energy homeostasis. The neurotransmitter(s) mediating 
the modulation of GnRH neurons downstream of leptin-induced activation of PMv neurons are not 
fully elucidated but glutamate and nitric oxide have been implicated (157, 355, 595). 
In addition to the importance of leptin receptor expression in different brain regions, specific 
modulation of different signaling pathways downstream of the leptin receptor has been shown to 
differentially modulate reproductive function. Genetic modulation of leptin-induced STAT3 
signaling either through specific deletion of STAT3 in leptin receptor expressing cells (213) or by 
genetic introduction of leptin receptors that are unable to couple through STAT3, due to 
replacement of the Tyrosine residue at 1138 (247), is sufficient to cause an increase in body 
weight but has no impact on the onset of puberty or fertility. Specific deletion of STAT5 in leptin 
receptor expressing cells (213) also fails to impact reproductive function. This is perhaps 
surprising given that preventing leptin-induced phosphorylation of the leptin receptor at Tyr1077 
(450), the site that is thought to be important for STAT5 recruitment (219), causes impairments in 
the estrous cycle of female mice. Together these data indicate that another (as yet 
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underdetermined) leptin-induced signaling cascade dependent on phosphorylation of Tyr1077 
may be important for mediating leptin’s effects on reproduction in female mice. 
 
Thyroid hormone axis 
The hypothalamus-pituitary-thyroid (HPT) axis regulates the secretion of thyroid hormone which 
has critical functions including modulation of whole organism and cellular metabolism, 
cardiovascular function, growth, and development. Absence of leptin signaling is associated with 
hypothyroidism in ob/ob and db/db mice (37, 432). In rodents and humans calorie-
restriction/fasting leads to downregulation of the HPT axis as a compensatory mechanism to 
reduce energy expenditure in order to conserve resources during the absence of food (127, 490). 
Following the cloning of leptin, it was found that treatment with peripheral administration of leptin 
was sufficient to partially reverse the starvation/fasting-induced reductions in circulating 
triiodothyronine (T3) and thyroxine (T4) levels in mice, providing evidence of a physiologic role for 
leptin in wild-type animals in the integration of metabolic cues and the function of the thyroid 
hormone axis (8, 349). Leptin treatment could also reverse the fall in circulating T3 and T4 levels 
associated with calorie-restriction induced weight-loss in humans (490). 
Within the brain, leptin treatment in rodents reverses the fasting-induced reduction in pro-
thyrotropin-releasing hormone (proTRH) mRNA levels in neurons of the PVH, which are key 
regulators of thyroid-stimulating hormone (TSH) modulating its release from the pituitary. 
Subsequent studies by multiple independent groups have demonstrated that while leptin can 
directly activate thyroid releasing hormone (TRH) neurons within the PVH (247, 283), an indirect 
pathway via the ARCPVH melanocortin circuitry is also a critical mediator of the effects on 
leptin on nutritional regulation of the HPT axis (188, 247, 311, 421). This has been confirmed by 
electrophysiologic studies indicating that both leptin and α-MSH can induce firing activity of PVH 
TRH neurons (213). In diet-induced obesity it has been proposed that leptin-resistance in the 
ARC leads to underactivity of the indirect melanocortin mediated pathway and that the function of 
the HPT axis in the obese state is maintained principally by the direct action of leptin on PVH 
TRH neurons (453). Mutation of Tyr1138 in the leptin receptor is sufficient to impact the HPT axis 
indicating that activation of STAT3 downstream of the leptin receptor is a key transcriptional event 
in mediating leptin’s effects on the HPT axis (37). 
In addition to modulating the HPT axis at the level of the TRH neurons, leptin can also modulate 
the activity of the enzyme deiodinase type II (D2; the enzyme which converts T4 to T3) within the 
brain (80), including the hypothalamus. D2 has been proposed to play a role in regulating the 
activity of ARC melanocortin neurons via modulation of uncoupling protein 2 (UCP2)(130); as 
such, modulation of hypothalamic D2 activity may represent another mechanism by which leptin 
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exerts its effects on whole organism metabolism, although this is an area that requires further 
study. 
 
CNS mediated effects of leptin on cardiovascular and renal function 
Cardiovascular disease is one of the key comorbidities associated with obesity, with elevations in 
blood pressure believed to be one of the key underlying factors (166, 460). Over the years, 
hyperinsulinemia (236), endothelial dysfunction (511), inflammation (238, 274), alterations in fluid 
homeostasis (237) and changes in sympathetic function (153) have all been implicated in 
mediating obesity-associated cardiovascular pathology. As the focus of this review is CNS targets 
of leptin, we will focus on how centrally acting leptin may modulate cardiovascular function; but 
leptin may also impact cardiovascular function via direct action on the heart and kidney as leptin 
receptors are known to be expressed in these organs (345, 592) . 
Obesity-associated increases in sympathetic nervous system activity in animals and humans has 
been implicated in mediating hypertension (486, 534, 624). The link between the sympathetic 
nervous system and obesity-associated hypertension was further supported by early mechanistic 
studies in animal models indicating that renal denervation prevented high-fat diet induced 
increases in arterial pressure and alterations in sodium retention (299).  
The importance of leptin in modulating sympathetic nervous system activity was discovered soon 
after its initial cloning. In rodents, peripheral administration of leptin increased norepinephrine 
turnover in BAT (123) and sympathetic nerve activity in BAT, kidneys and adrenal glands (251). 
In conscious non-obese rats, chronic peripheral infusion of leptin increases arterial blood 
pressure (517), an effect that can be blocked by administration of adrenergic receptor blockers 
(86). These experiments directly implicated leptin-mediated activation of the sympathetic nervous 
system in the modulation of the cardiovascular system. The effects of leptin on blood pressure in 
non-obese animals can also be seen following direct administration into the CNS via 
cerebroventricular infusion (93, 131, 162); these effects were attenuated by central administration 
of a melanocortin receptor antagonist implicating the central melanocortin system in mediating, at 
least in part, the CNS-mediated cardiovascular effects of leptin (134, 163). 
Despite profound obesity mice with defective leptin signaling, leptin-deficient ob/ob mice and 
db/db mice with defective leptin receptors, fail to show the predicted increase in blood pressure 
seen in diet-induced obese animals with comparable body weight (382, 522). This is in contrast to 
the obese agouti yellow mouse with defects in central melanocortin signaling which has the 
predicted obesity-associated increase in blood pressure (9, 382). This further suggests that leptin 
exerts important effects on cardiovascular function independent of the central melanocortin 
system. Surprisingly, leptin-replacement in ob/ob mice (leading to serum levels comparable to 
Page 29 of 119 Comprehensive Physiology
  30 
those seen in diet-induced obese mice) causes an increase in heart rate and blood-pressure 
despite a reduction in body weight (522). This was not due to an increase in physical activity as 
the leptin-treated ob/ob animals remained hypoactive compared with their lean and diet-induced 
obese wild-type counterparts. In agreement with what was seen in the animal models, genetically 
mediated loss of leptin-signaling (either lack of leptin or defective receptor function), although rare 
in humans, is also associated with lower blood-pressure compared with age and body-mass 
index (BMI) matched controls (522).  
Within the CNS a number of brain regions have been implicated in mediating the cardiovascular 
effects of leptin. In anaesthetized rats, direct administration of leptin into the hypothalamus, 
specifically the ARC (469) or VMH (383), significantly increased arterial blood pressure and renal 
sympathetic nerve activity but had no impact on heart rate. In contrast, direct injection of leptin 
into the DMH failed to impact renal sympathetic nerve activity while increasing arterial blood 
pressure and heart rate (383). This is further supported by studies indicating that loss of leptin 
signaling specifically in the DMH of mice (via either antibody-mediated or viral-induced 
knockdown of leptin receptors) is sufficient to attenuate diet-induced obesity associated increases 
in heart rate and blood pressure (522).  Perhaps surprisingly given its role in mediating renal 
sympathetic outflow (640), injection of leptin directly into the PVH of the hypothalamus did not 
impact any of the parameters measured (383). Together these data implicate discrete 
hypothalamic nuclei in mediating the cardiovascular effects of leptin.  
The SFO is a circumventricular site which is important in the regulation of autonomic functions 
including those associated with the cardiovascular system. The long-form of the leptin receptor is 
expressed in the SFO (528) and direct inject of leptin into the SFO of lean rats dose dependently 
decreased blood pressure but not heart rate, an effect that is absent in obese animals (529). 
Specific viral-mediated deletion of leptin receptors from the SFO prevents leptin induced 
increases in renal sympathetic nerve activity but has no impact on leptin-induced changes in food 
intake, body weight or sympathetic nerve activity in brown adipose tissue, suggesting that the 
functional role of leptin-signaling in the SFO is highly specialized (528).  
The baroreceptor reflex is a rapid homeostatic mechanism for the maintenance of blood pressure 
via the regulation of cardiac parameters including heart rate. Within the CNS, autonomic 
regulatory neurons in the brainstem found in the NTS and VLM, are key in mediating this critical 
homeostatic feedback loop (137); these are key sites of leptin receptor expression in the rodent 
brainstem (400). Microinjection of leptin in to the NTS of anaesthetized rats attenuates the 
reduction in heart rate associated with increased arterial pressure induced by intravenous 
administration of the α1-adrenergic receptor agonist phenylephrine, indicative of a negative effect 
of leptin on baroreflex sensitivity (15). In contrast, in the same study NTS leptin administration 
failed to impact the compensatory increase in heart rate associated with intravenous sodium 
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nitroprusside-induced decreases in arterial pressure, or acutely impact resting arterial pressure or 
heart rate. Together these data suggest that NTS leptin may specifically modulate the 
parasympathetic arm of the baroreflex (15); however, further data also exist that suggests that 
forebrain and not brainstem sites are important in modulating leptin’s effects on the baroreflex 
(356). In addition to modulating parasympathetic activity, data suggests that administration of 
leptin into the caudal (but not rostral) NTS increases sympathetic nerve activity in the kidney, yet 
not BAT (381) implying regional differences in the actions on leptin on cardiovascular parameters 
within the NTS.  
In addition to the NTS, the RVLM is an important site for regulation of sympathetic nervous 
system control of cardiovascular functions (137). Retrograde tracing studies indicate that leptin 
receptor expressing cells of the RVLM innervate the kidney and microinjection of leptin directly 
into the RVLM increases arterial pressure and renal sympathetic nerve activity in anaesthetized 
rats (34) supporting a role for this brainstem nucleus in mediating the effects of leptin on 
cardiovascular function. 
Leptin receptors utilize a number of different signaling pathways to exert their downstream 
effects. Interestingly, while diet-induced obesity in rodents is associated with an attenuated 
response to the effects of leptin on food intake and sympathetic nerve activity in BAT (indicative 
of leptin resistance) the leptin-induced increase in renal sympathetic nerve activity remains intact 
(470). This suggests that different pathways are responsible for mediating the leptin-mediated 
effects on sympathetic activity to different organs. 
Pharmacological and transgenic technologies have enabled the dissection of the relative 
contribution of different CNS leptin signaling pathways in cardiovascular physiology. Loss of 
endogenous homeostatic modulation of leptin signaling by SOCS3 (which itself inhibits leptin 
signaling) and SHP-2 (which enhances ERK mediated leptin signaling) following genetic mutation 
in Tyrosine985 of leptin receptors in mice   [Lepr
L985
 (l/l) mice] results in animals with elevated 
blood pressure and heart rate compared to littermate controls, without any notable impact on 
body weight (245). Leptin treatment in the l/l mice further elevated their blood pressure, heart rate 
and renal sympathetic activity compared to controls. In contrast, the leptin-induced increase in 
BAT sympathetic nerve activity is attenuated in l/l mice further emphasizing the divergent 
pathways regulating leptin induced control of renal- and BAT-sympathetic nerve activity (245). 
Complementary studies indicate that pharmacological inhibition of CNS ERK1/2 signaling has no 
effect on leptin induced increases in sympathetic activity in the kidney and adrenal gland but 
abolishes the leptin-induced increase in sympathetic activity in BAT (471). Together these studies 
indicate that endogenous negative feedback on the leptin signaling mediated via SOCS3 is 
necessary for normal cardiovascular regulation, while leptin receptor induced activation or 
ERK1/2 signaling is a key pathway regulating BAT but not renal sympathetic nerve activity. 
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Further work in the same area indicates that leptin-induced increases in sympathetic activity in 
the kidney, but not the adrenal gland and BAT, are inhibited by pharmacological CNS blockade of 
PI3K (468, 471), suggesting that this signaling pathway may be more critical in mediating the 
leptin-induced modulation of sympathetic activity which modulates cardiovascular function. 
While less widely studied, in addition to (or likely upstream of) modulation of the autonomic 
nervous system, leptin has also been shown to modulate the activity of neuroendocrine systems 
regulating cardiovascular function (237). The renin-angiotensin system (RAS) has been 
implicated in mediating obesity-associated hypertension (238). Exogenous leptin treatment 
regulates gene expression of key elements of the RAS system in the rodent brain and periphery 
(258, 259). Notably in the CNS, intracerebroventricular administration of leptin increases gene 
expression of angiotensin-receptor 1a (AT1aR) and angiotensin-converting enzyme (ACE) mRNA 
in the SFO and AT1aR mRNA in the ARC (259). Additionally, in the same study it was shown that 
pharmacological inhibition of RAS centrally using intracerebroventricular administration of 
losartan or captopril attenuated leptin induced increases in renal and BAT sympathetic nerve 
activity (259), an effect also seen in AT1aR-deficient mice. Central administration of leptin 
enhances the hypertensive effect of Angiotensin-II treatment, likely through enhancing CNS RAS 
signaling (615), and may represent an underlying mechanism for the enhanced hypertensive 
effect of Angiotensin-II treatment associated with diet-induced obesity in rats (614). 
 
Evidence for a role of leptin in modulating cognitive function 
Obesity is associated with altered cognitive function in both adults and children (for review see 
(543)). Numerous studies have demonstrated a correlative relationship between circulating leptin 
levels and altered cognitive function in humans (69, 263, 335, 553) but this is not consistently the 
case across all studies (431, 553, 560) and causation has yet to be definitively proven. 
The hippocampus is a key site for modulating emotion, learning and memory formation and is 
known to express leptin receptors (398). As discussed earlier in this review, there is evidence for 
changes in hippocampal structure and function in animals with congenital leptin-signaling defects 
(147, 212, 361, 544) providing evidence for a role of leptin in mediating functional hippocampal 
development. However, evidence also indicates a potential role for leptin in enhancing cognition 
via modulation of hippocampal function in animals without congenital leptin-deficiency (287). Both 
in vivo (597) and in vitro experiments (the latter performed in hippocampal slices) showed that 
exogenous leptin induces LTP, likely via glutamatergic [N-methyl-D-aspartate (NMDA)] receptor 
dependent mechanisms (372, 434, 515). Additional modulatory actions of leptin that support a 
role of leptin in modulating hippocampal synaptic plasticity include reversal of evoked LTP (411) 
and induction of long-term depression (LTD) in recording conditions that promote enhanced 
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excitability (165). In vitro, leptin can stimulate filopodial density and motility, and ultimately 
synapse formation in cultured hippocampal neurons (429), providing a mechanistic basis for the 
enhanced LTP seen following leptin administration. At the molecular level, leptin-induced 
dendritic spine formation in the hippocampus appears to require activation of the 
calcium/calmodulin-dependent protein kinase II (CaMKII) signaling cascade and transient 
receptor potential cation (TRPC) channels (147, 434). These molecular and neurophysiologic 
changes are reflected in an ability of peripherally administered leptin to enhance the performance 
of rodents in hippocampal-dependent spatial learning tasks, such as the Morris water maze (434). 
Based on its ability to enhance cognitive function (434) and enhance hippocampal synapse 
formation  in animal models (148, 429, 434), leptin has also been explored as a potential 
therapeutic agent in neurodegenerative diseases such as Alzheimer’s disease (AD) in which loss 
of hippocampal function is a key pathologic feature. In vitro, in neuronal cultures and mouse brain 
extracts, leptin can reduce amyloid-beta (Aβ) secretion (190, 223) and tau-phosphorylation (156, 
222-224), which are believed to play a key role in AD pathogenesis. Functionally, leptin can 
prevent the negative effects of Aβ on LTP in vitro and reduce Aβ-induced neuronal cell death via 
a STAT3 mediated mechanism (156). The functional relevance of these in vitro studies are 
confirmed by in vivo work that demonstrates that chronic exogenous peripheral leptin treatment is 
able to reduce pathologic features and enhance cognitive performance in a transgenic mouse 
model of AD (221, 222). These effects have also been recapitulated in a distinct animal model of 
AD by an independent research team using a viral-gene delivery approach to enhance leptin 
levels directly in the brain (454). In normal rats, chronic intracerebroventricular leptin is able to 
attenuate the impairments in both spatial memory and hippocampal LTP induced by a single 
acute intracerebroventricular injection of Aβ 1-42 peptide (566). These animal studies are 
promising, but further work is needed to determine how these findings may translate to humans. 
 
Adiponectin 
Adiponectin is a 244 amino acid protein secreted by adipose tissue (273) which circulates in 
human plasma at ~1.9-17.0 mg/ml in the form of homomultimers of trimers, hexamers and high 
molecular weight multimers (HMW) (14, 419, 588). The protein has an N-terminal domain 
containing collagen repeats whereas the C-terminal has a globular structure which, when cleaved 
from the mature protein by leukocyte elastase released by monocytes/neutrophils (589), 
produces globular adiponectin (gAd). The gAd has distinct pharmacological properties from the 
HMW (3, 198). Mutations within the gene alter the formation of di-sulfide bonds, which impact the 
ability of adiponectin to form larger HMW. For example, human mutations G90S and G84R 
prevent adiponectin from forming HMW (588) and are associated with diabetes (584). Moreover, 
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adiponectin is also post-translationally modified at a number of leucine residues within the 
globular domain (specifically, residues 68, 71, 80 and 104) and mutation of these residues to 
arginine, prevents hydroxylation and glycosylation, which abrogates the formation of HMW (594). 
Importantly, prevention of lysine modification of adiponectin reduces the ability of adiponectin to 
stimulate AMPK in the liver. Furthermore, treatment of obese db/db mice with non-post-
translationally modifiable adiponectin (at lysine residues 68, 71, 80 and 104) severely diminishes 
the ability of adiponectin to reduce hyperglycemia, hyperlipidemia and insulin resistance, 
suggesting that hydroxylation and glycosylation of adiponectin plays an important role in the 
insulin-sensitizing function of adiponectin (594). Mutations in the gene have also been reported to 
alter adiponectin secretion. A mutation resulting in an isoleucine to threonine change at position 
164 (I164T) alters the secretion of adiponectin from adipocytes and is associated with the 
presence of metabolic syndrome (312).  
Generally, plasma levels of adiponectin are higher in females than males (124, 440) and 
circulating levels are significantly lower in people with type-2 diabetes (T2D) (268) and obesity 
(14), but higher in those with type-1 diabetes (T1D) (379). Adiponectin mRNA expression and 
secretion from mouse 3T3-L1 adipocytes in vitro is downregulated by proinflammatory stimuli 
such as IL-6 and tumor necrosis factor (TNF) α (73, 187) through a mechanism partly dependent 
on intact p42/44 MAPK signaling (187). Adiponectin secretion can be increased following weight 
loss (73), suggesting that changes in adiponectin expression and secretion are sensitive to and 
respond to the inflammatory stimuli associated with diet-induced obesity. Moreover, adiponectin 
expression is enhanced by thiazolidinedione (TZD) treatment, in a peroxisome proliferator-
activated receptor (PPAR) γ2-dependent manner (230, 375) in insulin-resistant humans and 
rodents (375).  
Adiponectin-deficient mice were generated in 2002; heterozygote mice were reported to be mildly 
insulin-resistant, whereas the homozygote knockout animals were moderately insulin resistant 
and glucose intolerant (332, 420), overall, suggesting a critical role for adiponectin in the 
maintenance of glucose homeostasis. The defects in glucose homeostasis in null animals are 
exacerbated by high-fat feeding (420), an effect which may be related to elevated plasma TNFα 
and reduced free fatty acid clearance (374).  Nawrocki et al., (2006) also demonstrated that 
induction of muscle and liver AMPK activity by TZDs was absent in adiponectin null animals, 
indicating that at least in part, the therapeutic benefit of TZDs is dependent on intact adiponectin-
AMPK signaling. This is further strengthened by the observation that pioglitazone-induced 
improvement in hepatic insulin resistance in ob/ob mice is ablated in adiponectin null ob/ob mice 
(331). 
Adiponectin knockout animals are resistant to high-fat diet-induced obesity, primarily mediated by 
increased leptin sensitivity (333). In addition to having alterations in glucose homeostasis, 
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adiponectin-null animals have increased vascular damage following external vascular cuff injury, 
supporting a role for adiponectin in maintaining vascular health (332).  
Adiponectin entry into the brain 
The origin of adiponectin that activates CNS receptors is debated. Adiponectin is found in the 
CSF from humans and mice; however, the CSF:plasma ratio varies between species. For 
example, in mice the CSF concentration of adiponectin is approximately 1-4% of plasma (464) 
whereas in humans, the CSF concentration of adiponectin is lower, at approximately 0.1% of 
plasma (325, 334); although it should be noted that not all studies have detected adiponectin in 
the CSF of humans (535).  
Recent evidence suggests that adiponectin can directly permeate the BBB. In adiponectin null 
animals’ adiponectin was detected in CSF samples taken three hours after injection of trimeric 
adiponectin, indicating that the low molecular weight adiponectin can directly enter into the CNS 
from the circulation (621). 
 
Adiponectin receptors 
Adiponectin has two receptors termed AdipoR1 and AdipoR2, which were cloned in 2003 (588). 
AdipoR1 in humans and mice share 96.8% homology and the AdipoR2 shares 95.2% identity 
(617). While not G-protein coupled, both receptors have 7 transmembrane domains and have 
proteins with predicted molecular masses of 42.4 kDa and 35.4 kDa for mouse AdipoR1 and 
AdipoR2, respectively. AdipoR1 is relatively ubiquitously expressed, with the highest expression 
seen in skeletal muscle, whereas AdipoR2 is most abundantly expressed in mouse liver (617).  
AdipoR1 and R2 can interact with the adaptor protein APPL1 and in neurons adiponectin can 
stimulate a number of signaling pathways (figure 3) including the insulin receptor substrate1/2 
(IRS1/2) pathway leading to increased Akt (serine 473) and ERK (threonine 202/tyrosine 204) 
phosphorylation (128). Adiponectin can also stimulate the JAK2-STAT3 pathway (128), 
increasing tyrosine 705 phosphorylation, which is required for transcriptional activation. The 
adipokine can also activate the AMPK pathway (333), increasing threonine 172 phosphorylation, 
which greatly enhances kinase activity. In some cell types, particularly vascular endothelial cells, 
adiponectin can increase eNOS (serine 1177) phosphorylation via the AMPK pathway (422), 
leading to increased nitric oxide production. This is a neuroprotective pathway and is discussed in 
more detail below. 
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Adiponectin receptors in the CNS 
Within the CNS, both AdipoR1 and AdipoR2 are found in the hypothalamus in post-mortem 
human tissue; although, AdipoR1 is expressed throughout the hypothalamus, whereas AdipoR2 
is restricted to the PVH (325). In mouse, AdipoR1 is found in the cortex, hippocampus, striatum, 
thalamus and hypothalamus (table 4). Within the hypothalamus, AdipoR1 is localized within the 
supraoptic nucleus (SON), PVH and ARC (229). AdipoR2 expression is less widespread, being 
limited to regions of the cortex, hippocampus, amygdala, thalamus and anterior cingulate cortex 
(ACC) (316) (table 5). Within the hypothalamus, AdipoR2-expressing cells are found within the 
anterior hypothalamic area (AHA) and LHA, perifornical region, SON, PVH and ARC. Within the 
mouse hypothalamus, AdipoR1 and AdipoR2 are located on both NPY and POMC neurons (229) 
and on warm-sensitive neurons of the POA, that control the regulation of core body temperature 
(316). 
The expression of both receptor types in the CNS is predominately neuronal although AdipoR1 
and AdipoR2 expression is found on GFAP-positive cells, on ependymal cells and tanycytes 
lining the third ventricle (229). Adiponectin receptors are also expressed within the endothelial 
cells of the BBB (535), suggesting that some of the metabolic effects of adiponectin may be 
mediated by altered signaling in brain microvascular endothelial cells. 
Adiponectin in neurodevelopment and neurogenesis 
High-fat feeding is known to reduce hippocampal neurogenesis in rats (362) and mice (446), with 
neurogenesis within the dentate gyrus being particularly sensitive to alterations in metabolic state. 
Moreover, exercise is a known stimulator of neurogenesis in the dentate gyrus (582). Yau and 
colleagues (2014) investigated whether the exercise-induced changes in hippocampal 
neurogenesis were dependent on intact adiponectin signaling. They found that after running, 
hippocampal levels of adiponectin were significantly elevated, in the absence of any changes in 
AdipoR1, AdipoR2 or the downstream adaptor protein APPL1. Moreover, adiponectin-null 
animals had diminished running-induced hippocampal neurogenesis, in the absence of any 
changes in baseline neurogenesis, suggesting that adiponectin specifically regulates exercise-
induced neural cell proliferation (621). This work was complemented by another study indicating 
that adiponectin application can increase the proliferation of cultured hippocampal neural stem 
cells/progenitors isolated from adult rats. In these cells, adiponectin activated both AMPK and 
p38 MAPK, however, only p38 MAPK signaling was involved in adiponectin-induced proliferation, 
as inhibition of this kinase using SB203580 blocked the effect of adiponectin, whereas inhibition 
of AMPK using compound C was without effect on proliferation (632). 
In addition to neural stem cell proliferation, data suggests that adiponectin may also exert trophic 
effects on neuronal outgrowth. Loss of adiponectin results in decreased dendritic length, reduced 
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branching and spine density in hippocampal dentate gyrus granule neurons, whereas infusion of 
adiponectin increased dendritic spine density (633).  
 
Adiponectin and regulation of food intake 
As described above, AdipoR1 and AdipoR2 are expressed within the hypothalamus. Specifically, 
both receptors are expressed in NPY and POMC neurons within the ARC (229). Intravenous 
administration of adiponectin increases food intake in mice (333) and stimulates the activity of 
hypothalamic AMPK, a known driver to food intake (403). Interestingly, adiponectin-induced 
increases in food intake are dependent on AdipoR1-mediated activation of AMPK. Knockdown of 
AdipoR1 prevents adiponectin-induced increases in hypothalamic AMPK, whereas knockdown of 
AMPK prevents adiponectin-induced increases in food intake (333). Adiponectin-null animals 
have significantly reduced basal AMPK phosphorylation in the hypothalamus, suggesting a 
constitutive role for adiponectin in stimulating hypothalamic AMPK activity. 
In contrast, another study has suggested that adiponectin action in the hypothalamus decreases, 
rather than increases food intake (128). In this study, adiponectin was administered directly into 
the cerebroventricular system in the brain (intracerebroventricular) as opposed to the intravenous 
injection utilized by Kubota and colleagues (333). The central administration study by Coope et al 
(128) went on to demonstrate that adiponectin predominantly utilizes AdipoR1 to alter metabolism 
and that activation of this receptor recapitulated key features of insulin and leptin-induced 
signaling pathways, namely activation of the IRS-Akt-forkhead box protein 01 (FOXO1) pathway 
and the JAK2-STAT3 pathway (128). A 2016 study by Sun et al demonstrated that adiponectin 
and the small molecular AdipoR agonist AdipoRon excited ARC POMC-expressing neurons 
(545). This study also showed that adiponectin could directly inhibit ARC NPY/AgRP neurons via 
the activation of the ATP-sensitive K
+
 channel (KATP). Therefore suggesting that adiponectin could 
inhibit feeding via direct activation of POMC neurons and simultaneous inhibition of NPY/AgRP 
neurons, thus reducing inhibitory synaptic input onto POMC neurons (545). The discrepancies in 
the effect of central compared with peripheral administration of adiponectin on food intake may be 
dependent on ambient glucose concentrations. During fasting, intracerebroventricular injection of 
adiponectin significantly decreases food intake; however, co-injection of glucose with adiponectin 
stimulated food intake (548). This divergence may be explained by differential regulation of ARC 
POMC neurons at differing glucose concentrations. Using ex vivo slice patch clamp experiments 
in POMC-hrGFP mice, application of adiponectin in the presence of high glucose (10 mM) 
induced hyperpolarization of POMC neurons, in an AMPK dependent manner. Whereas, during 
lower glucose (euglycemic; 5 mM), adiponectin depolarized POMC neurons in a PI3K-dependent 
manner. It should also be noted that the study by Sun et al 2016, also noted adiponectin-induced 
depolarization of POMC-expressing neurons, however, further lowering of extracellular glucose 
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over the physiological range (0.5-5 mM) failed to modify the adiponectin response (545). This 
suggests that supraphysiological glucose levels, where AMPK is sufficiently inhibited, may modify 
the adiponectin response. 
Adiponectin may also play a role in treatment-induced changes in body weight in T2D. For 
example, while TZDs are anti-hyperglycemic drugs, they can promote weight gain. One 
mechanism by which this is believed to occur is via the action of TZDs as agonists of PPARγ, 
leading to lipogenesis, fluid retention and increased appetite. TZDs are also known activators of 
AMPK signaling in the periphery (201, 496) and in the brain (466), and recent evidence suggests 
that the TZD pioglitazone (PIO) increases food intake, adiposity, body weight and reduces energy 
expenditure via a mechanism requiring ARC AdipoR1-mediated activation of AMPK (466). 
Following PIO treatment, animals had increased serum levels of adiponectin and, despite weight 
gain observed in PIO-treated animals, hypothalamic leptin and insulin-sensitivity were improved 
as indicated by the restoration of insulin-induced Akt phosphorylation and leptin-induced pSTAT3 
in high-fat fed animals. This improved leptin and insulin sensitivity was also reflected in a 
restoration of leptin and insulin-induced decrease in acute food intake in PIO-treated mice (466).  
 
Adiponectin and thermogenesis 
In addition to impacting energy homeostasis by modulating food intake, recent evidence suggests 
that adiponectin may play a role in modulating energy expenditure/adaptive thermogenesis. Hui 
and colleagues (2015) demonstrated that adiponectin expression is significantly increased in the 
subcutaneous WAT (scWAT) of mice exposed to chronic cold (277). Moreover, this accumulation 
of adiponectin in scWAT was associated with increased browning of WAT, driven by an 
enhancement of anti-inflammatory M2 macrophage accumulation in this tissue. Treatment of 
mature adipocytes with adiponectin increased the expression of uncoupling protein 1 (UCP1), a 
marker of brown adipose tissue, which was blocked by the AMPK inhibitor Compound C. 
Moreover, the accumulation of adiponectin was not dependent on AdipoR1 or AdipoR2, but 
instead the effect was mediated by T-cadherin, which was predominantly expressed on M2 
macrophages (277). Taken together, these data suggest that adiponectin drives browning of 
scWAT.  
Further indirect evidence for a role for adiponectin in regulating thermogenesis comes from the 
study by Kolumam et al (323). This group used an antibody to activate the fibroblast growth factor 
1 (FGF1)/βKlotho complex, which when administered produced a variety of beneficial effects in 
both mice and monkeys, including increased energy expenditure, browning of WAT, weight loss 
and improved glucose and lipid homeostasis. Importantly, the levels of HMW adiponectin were 
significantly increased in animals treated with the FGF1/βKlotho-activating antibody and loss of 
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adiponectin partially reduced the beneficial metabolic effects. The authors propose that the later 
beneficial effects of the antibody are mediated by adiponectin-dependent browning of WAT. In 
this study however, it should be noted that the effect of FGF1/βKlotho antibody on insulin-
sensitization was independent of adiponectin (323).  Further indirect evidence suggests that 
adiponectin may promote thermogenesis as the study by Hou et al (269) determined that 
treatment of mice on a high fat diet with irisin, a myokine released from exercising muscle, 
increased circulating adiponectin and increased markers of browning on WAT, UCP1 and Cidea 
(269). Although this study did not determine whether browning of WAT by irisin required 
adiponectin, but it does suggest that adiponectin may be involved.  A central effect of adiponectin, 
may at least in part, contribute to the regulation of heat production as AdipoR1 and AdipoR2 
expression has been detected on warm-sensitive neurons within the POA of the hypothalamus, 
which is involved in thermoregulation. Moreover, central adiponectin injection into the POA 
increases core body temperature with a concomitant decrease in respiratory exchange ratio 
(RER), indicating increased lipid oxidation (316). This study demonstrated that both AdipoR1 and 
AdipoR2 contributed to heat production as knockout of either receptor blunted the adiponectin-
induced changes in core body temperature. Interestingly, only loss of AdipoR1 altered the 
decrease in RER, suggesting that AdipoR1-expressing POA neurons are involved in regulating 
lipid oxidation/activation of brown adipose tissue, whereas AdipoR2-expressing neurons do not 
(316). 
These studies are in contrast to the study by Qiao and colleagues who demonstrated a 
suppressive role for adiponectin in browning of adipose tissue (465). In this study, adiponectin 
knockout animals displayed a higher core body temperature than wild-type mice suggesting a 
repressive role for adiponectin on browning of adipose tissue during cold exposure. Moreover, 
viral overexpression of adiponectin in wild-type mice suppressed UCP1 expression in brown 
adipose tissue, which occurred without a change in mitochondrial DNA copy number (465). This 
study also demonstrated that adiponectin overexpression reduced β3 adrenergic receptor-
mediated lipolysis and thermogenesis. Clearly, further research is required to determine the role 
of adiponectin in regulating browning of WAT/thermogenesis and under which conditions this 
adipokine may play a positive or negative role in promoting thermogenesis. 
 
Adiponectin and reproduction 
Adiponectin levels increase from birth to adulthood in mice, with the increase larger in female 
than male mice (124). Moreover, during pregnancy the levels of adiponectin decrease from the 
2
nd
 trimester onwards in mice, correlating with the change in circulating prolactin. Direct infusion 
of prolactin in female mice has also been shown to decrease circulating adiponectin levels (124). 
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In humans, adiponectin levels also decline during pregnancy, reaching a nadir during lactation 
(19), moreover, direct application of prolactin to primary cultures of adipocytes decreased 
adiponectin expression and secretion, suggesting that prolactin drives down adiponectin 
expression during lactation to promote the storage of fat.  
Adiponectin and AdipoR2 are expressed in the human placenta, specifically localized to 
cytotrophoblast and syncytiotrophoblast cells (82). Treatment of human placental tissue with gAd 
has been reported to paradoxically increase the release of proinflammatory cytokines IL-1β, IL-6, 
TNFα and prostaglandins E2 and F2α in an ERK1/2 dependent manner (337). Moreover, the 
adiponectin expressed in human placenta is secreted and can stimulate ERK1/2 and p38 MAPK 
signaling when conditioned media from human placental tissue is added to HEK292 cells 
expressing AdipoR1 (102). The placental expression of adiponectin is decreased in gestational 
diabetes (102), correlating with the decreased circulating levels seen in women with gestational 
diabetes (481, 605).  The decreased placental production of adiponectin is likely driven by 
proinflammatory cytokines directly, as application of TNFα, interferon (IFN)-γ and IL-6 all acutely 
decrease adiponectin secretion from this tissue (102). 
In mice, transgenic overexpression of adiponectin produces female mice that are infertile (125). 
Moreover, women with T1D are subfertile compared to the general population (295) and have 
been shown to have higher circulating adiponectin levels (379), including throughout the 
gestational period (474). Importantly, the pituitary gland expresses adiponectin and both AdipoR1 
and AdipoR2 (462), specifically within the growth hormone (GH), FSH-, LH- and TSH-producing 
cells. Using LβT2 pituitary gonadotropic cells, Lu and colleagues demonstrated a functional role 
for adiponectin in regulating LH secretion. This study showed that LβT2 cells expressed both 
AdipoR1 and AdipoR2 and treatment with adiponectin led to increased AMPK activation, which 
was accompanied by decreased LH secretion (which could be mimicked by pharmacological or 
genetic activation of AMPK). This indicates that the suppression of LH is directly mediated 
through activation of the AMPK pathway (370). 
There is also evidence to suggest that adiponectin may influence the hypothalamic-pituitary-
gonadal (HPG) axis at the level of the hypothalamus. Adiponectin has been reported to inhibit 
GnRH release from cultured hypothalamic GT1-7 cells and in primary mouse hypothalamic 
cultures in an AMPK-dependent manner (107, 320, 601).  As described in the section on leptin 
and reproduction above, kisspeptin is the peptide hormone encoded by the Kiss1 gene 
responsible for initiating GnRH release at puberty. Adiponectin inhibits Kiss1 mRNA production in 
GT1-7 cells, also via an AMPK-dependent pathway (600). Together, these data suggest that 
increased adiponectin levels associated with starvation/negative energy balance, decrease 
fertility and puberty via a mechanism involving the suppression of GnRH and LH secretion in the 
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hypothalamus and pituitary, respectively. Indeed, increased adiponectin levels may explain 
reduced fertility and the delayed onset of puberty seen in T1D (364). 
 
Bone, energy homeostasis and adiponectin 
Osteoblasts and osteoclasts are bone-specific cells that have recently been described as playing 
a role in maintenance of energy metabolism. Interestingly, mice genetically engineered with loss 
of osteotesticular protein tyrosine phosphatase (OST-PTP) specifically in osteoblasts are lean, 
protected from high fat diet-induced obesity and are hypoglycemic (347). This is mediated by 
hyperinsulinemia due to increased β-cell proliferation combined with increase insulin sensitivity. 
These animals also display specific hyperadiponectinemia without changes in other circulating 
adipokines (347). Moreover, co-culture osteoblasts with adipocytes, increased adiponectin 
expression and loss of OST-PTP further enhanced adiponectin expression, suggesting that a 
molecule secreted from osteoblasts mediated this response. Furthermore, the 
hyperinsulinemic/hypoglycemic phenotype of OST-PTP deficient mice could be rescued by 
deletion of a single copy of osteocalcin, a molecule specifically secreted from osteoblasts, 
suggesting that osteocalcin directly regulates adiponectin production and β-cell proliferation 
(347). Interestingly, the link between bone and adiponectin levels may be reciprocal since 
adiponectin knockout mice have a higher than normal bone density at 6 weeks of age, whereas 
adiponectin-overexpressing mice have decreased bone mass (297). However, older adiponectin 
knockout mice develop low bone mass mediated by decreased proliferation of osteoblasts. This 
led Kajimura and colleagues to speculate that perhaps loss of adiponectin at older ages led to 
increased sympathetic nervous system activation, which is a stimulator of bone reabsorption 
(173).  This group partially reduced sympathetic tone by removing one copy of dopamine β-
hydroxylase (an enzyme involved in catecholamine synthesis), in mice and crossed these with 
adiponectin-null mice. The resulting offspring showed maintained bone mass at later stages of 
life, mediated by increased osteoblast proliferation and increased bone mass (297). Taken 
together, these studies suggest a complex interplay between the peripheral and central effects of 
adiponectin on bone formation and metabolism.  
 
Adiponectin and mood disorders 
Adiponectin has been proposed to have anti-depressive/anxiolytic actions in the CNS. For 
example, correlative data indicates that plasma adiponectin levels are decreased in patients with 
major depressive disorder (350, 354) and bipolar depression (280), independently of effects on 
body weight. A potential mechanism of action of the anti-depressive effects of adiponectin is via 
an anti-inflammatory action. For example, direct injection of adiponectin into the CNS decreases 
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pro-inflammatory cytokine expression in microglia from chronically stressed mice (95). 
Furthermore, the ability of environmental enrichment to reduce stress and the elevations in CNS 
proinflammatory cytokines (IL-1β, IL-6 and TNFα) in the hippocampus and hypothalamus 
associated with the chronic administration of corticosterone in mice is lost in adiponectin-null mice 
(95). Together these data suggests that adiponectin signaling may modulate microglial activation 
and neuroinflammation in the CNS, which in turn could influence behavior.  
Patients with schizophrenia treated with antipsychotic drugs have been reported to present with 
low serum adiponectin, due to increased adiposity driven by the drug treatment (318, 319). 
Moreover, the alteration in adiponectin levels is drug specific. In humans, a prospective study 
found that plasma adiponectin levels were decreased in schizophrenic patients treated with 
olanzapine, but not those taking risperidone. Although both patient groups gained weight, the 
decreased adiponectin levels seen in the olanzapine group were associated with the most 
pronounced weight gain; however, the olanzapine-associated decrease in adiponectin levels 
were still significant after adjusting for BMI. Recent data suggests that individuals taking 
clozapine and olanzapine have significantly lower plasma adiponectin that those taking 
risperidone (36) and that low serum adiponectin levels in male patients is a specific marker for 
weight gain on clozapine treatment (319).   These metabolic side-effects of second generation 
anti-psychotics have a significant impact of patient welfare, leading to emotional issues related to 
weight gain and in some cases poor compliance with the treatment (576). 
 
CNS mediated effects of adiponectin on cardiovascular physiology 
A major component of the metabolic syndrome is the increased risk of cardiovascular disease, 
predominately driven by hypertension. Several studies have explored the links between low 
adiponectin levels and hypertension (2, 289, 304). The current data suggests that lower 
adiponectin levels correlate with higher blood pressure in both men and women (2, 304). A 
potential role for adiponectin in modulating cardiovascular physiology is further supported by 
studies which indicate that polymorphisms in adiponectin itself may underlie blood pressure 
responses to dietary salt intake. Single nucleotide polymorphisms (SNPs) at rs16861205 and 
rs822394 in the adiponectin gene were associated with diastolic blood pressure (DBP) response 
to low salt loading, with the latter SNP also being associated with mean arterial pressure in the 
Chinese Han population (115). These same SNPs were also associated with the DBP response 
to high salt loading. 
With the CNS the brainstem is an important integratory site for cardiovascular and autonomic 
sensory afferents, specifically the NTS, which is involved in the baroreceptor reflex which 
maintains blood pressure homeostasis. Neurons in the NTS express both the AdipoR1 and 
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AdipoR2 and infusion of adiponectin directly into the NTS in rodents has been reported to 
decrease blood pressure (270). This is mediated by modulation of the electrical activity of NTS 
neurons, with the majority of NTS neurons being excited by adiponectin and a proportion being 
inhibited. In single cell RT-PCR analysis, the majority of the cells depolarized by adiponectin were 
found to be NPY- and glutamic acid decarboxylase 67 (GAD67)-positive, suggesting that 
adiponectin acts on the AdipoR1 to depolarize NPY-containing neurons, thereby increasing 
GABAergic neurotransmission (270). 
An independent study also demonstrated that the electrical activity of neurons within the AP, 
which project to the NTS, are regulated by adiponectin. Neurons within the AP express both 
AdipoR1 and AdipoR2, and stratifying neuronal responses based on AdipoR expression, 
indicating that only the neurons which expressed both AdipoR1 and AdipoR2 tended to be 
electrically altered by adiponectin. In contrast to the work in the NTS (270), this study, 
demonstrated that adiponectin injection directly into the AP increased, rather than decreased, 
blood pressure (200). This suggests that the downstream regulation of blood pressure may 
require the integration of signals from a number of different brain nuclei and further work remains 
to be done to elucidate the CNS mediated effects of adiponectin signaling on cardiovascular 
physiology. 
 
Neuroprotective actions of adiponectin  
Adiponectin may play a role in protecting neurons during ischemic stroke. Recent data suggests 
that polymorphisms in both AdipoR1 and AdipoR1 are associated with an increased risk of 
ischemic stroke in a Chinese population (241, 626). This is supported by animal studies indicating 
that adiponectin-null animals have a larger infarct area following medial cerebral artery occlusion 
(MCAO) injury (an experimental model of ischemic stroke) compared to wild-type animals (422). 
This study also showed that adiponectin protein was localized to the endothelial compartment 
during transient ischemia, suggesting that adiponectin can accumulate at the site of injury, 
possibly entering via areas where the BBB is damaged. Moreover, administration of adiponectin 
using a viral approach could reduce infarct size in both wild type and adiponectin-null animals, an 
effect that was associated with the increased phosphorylation of endothelial nitric oxide synthase 
(eNOS). In this study, adiponectin-null mice also displayed reduced cerebral blood flow 
suggesting that adiponectin-induced activation of eNOS increases perfusion to reduce neuronal 
damage/death (422). A more recent study found that obesity caused by a Western diet (known to 
reduce circulating plasma adiponectin levels) in rats, increased MCAO injury and symptom 
scores of neurological deficits (610). The cellular damage in the hippocampus, striatum and 
frontal cortex and the neurological deficits could be partially rescued by viral transfer of 
adiponectin (610). 
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In sepsis, endothelial dysfunction is a major factor in organ damage, including damage to the 
brain. Sepsis increases platelet and leukocyte-adhesion in the cerebral microcirculation and this 
is augmented by the loss of adiponectin. These effects were accompanied by increased BBB 
dysfunction in these mice (578). Moreover, in obese mice, sepsis induced neuroinflammation, 
microvascular dysfunction and brain function are impacted more severely than reported in lean 
animals. Given that obesity is associated with lower adiponectin levels and the evidence 
suggesting obese individuals have an increased mortality during sepsis, it is plausible that the 
increased sepsis-associated mortality as seen in obesity may in part, be due to 
hypoadiponectinemia. 
Further evidence for a potential neuroprotective effect of adiponectin comes from animal models 
of epilepsy. In an experimental model of kainic acid (KA)-induced seizure activity, serum 
adiponectin levels decreased following KA treatment. This was accompanied by an increase in 
AdipoR1 expression in the hippocampus, without altering AdipoR2 expression (294). KA also 
significantly increased markers of cell death including TUNEL and caspase-3, which were all 
significantly reduced by pre-treatment with adiponectin for 24 hours (294). This study also 
demonstrated that KA-induced neuroinflammation (as measured by NFκB immunoreactivity) was 
also diminished by adiponectin, further demonstrating an anti-inflammatory role of adiponectin. 
Adiponectin also protects against glutamate-induced excitotoxicity in hippocampal neurons. For 
example, exposure of mouse hippocampal HT22 neurons to glutamate increases cleavage 
caspase-3, Bax/Bcl2 ratio and TUNEL staining, which is reversed by adiponectin treatment. This 
occurs by rescue of glutamate-induced decreases in SIRT1 and PGC1α (627). 
 
Adiponectin and neurodegeneration 
Obesity and diabetes are linked with increased risk for developing dementia (406), including AD 
(351, 371), with people with diabetes having an odds ratio of approximately 1.6 for risk of 
developing dementia. As mentioned above, adiponectin levels are decreased in obesity and 
diabetes and similarly, adiponectin levels have been reported as decreased in elderly people with 
mild cognitive impairment (MCI) and AD when compared to cognitively healthy age-matched 
controls (558). Moreover, in patients with T2D, those with MCI have significantly lower 
adiponectin compared to control individuals (T2D without MCI) (220). As mentioned above in AD, 
a key hallmark is the presence of Aβ-plaques. In a cell based study, adiponectin can protect 
against Aβ-induced cytotoxicity during H2O2-induced oxidative stress (96). Furthermore, osmotin, 
which is a plant-based protein homolog of adiponectin, can improve neurological deficits in a 
mouse and cell model of AD (514). Treatment of Aβ-overproducing SH-SY5Y cells with osmotin 
reduced Aβ production via a mechanism requiring activation of AdipoR1, AMPK, SIRT1 and 
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inhibition of sterol-regulatory element binding protein 2 (SREBP2). The activation of AMPK and 
increased SIRT1 expression following osmotin treatment was also observed in mice with mutant 
amyloid precursor protein/presenilin 1 (APP/PS1) and this correlated with the improved 
performance in hippocampal-dependent memory tests (Morris Water Maze and Y-maze tests) 
(514). 
However, not all studies have found an association between circulating adiponectin levels and 
dementia. For example, in a Japanese population, Kitagawa and colleagues demonstrated that 
serum HMW adiponectin was not changed in patients with AD, vascular dementia (VAD) or other 
types of dementia (314). Similarly, Dukic and colleagues found no association between circulating 
adiponectin levels and AD, VAD or MCI (161). Conversely, two studies have identified positive 
correlations between adiponectin levels and MCI (306, 575).  Clearly the relationship between 
circulating/CSF adiponectin and dementia is complex. This is likely complicated by changes in 
appetite and weight with dementia progression, caused by eating disturbances and altered 
appetitive and swallowing capabilities (296). Indeed, weight-loss per se has been reported to 
increase circulating adiponectin levels (63, 329, 620). 
 
Adiponectin and glia 
Little is known about the role of adiponectin in regulating the function of glial cells within the brain. 
However, both AdipoR1 and AdiporR2 are present on human U373 astrocytoma cells and 
cultured human primary astrocytes (590). Furthermore, AdipoR1 is present on GFAP-positive 
cells within the rat ARC (229), suggesting that adiponectin may play a role in regulating glial cell 
function. In vitro data from human astrocyte cells has shown adiponectin to have a potential 
proinflammatory role, increasing the mRNA expression of IL-6, MCP-1, IL-1β and IL-8 and also 
increasing the secretion of IL-6 and MCP-1 (590). However, another study demonstrated that 
adiponectin injection into the brain promoted an anti-inflammatory phenotype in microglia and 
brain macrophages in a mouse model of depression (induced by chronic corticosterone 
administration) (95). It is not clear whether this anti-inflammatory effect is direct on the microglial 
cells, or by changes in astrocyte-microglia or neuron-microglial signals. Moreover, there is 
currently no data indicating that microglia or oligodendrocytes express adiponectin receptors. 
However, adiponectin-null mice treated with KA in order to induce seizes display microglial 
hypertrophy and clustering in the hippocampus, providing evidence of excessive gliosis, 
compared to wild-type mice (344). The potential role for adiponectin signaling in glial cell 
functions requires further study. 
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Other adipokines 
Excluding leptin and adiponectin, numerous adipokines have been identified that have been 
shown in experimental studies to exert physiologic actions via the CNS. One limitation of many of 
these studies is that some of these “adipokines” have themselves subsequently been found to be 
expressed in the CNS, making it challenging to differentiate the CNS-mediated effects of the 
peripherally-derived protein compared with those of the protein found in the brain. While this does 
not necessarily indicate that when these are proteins secreted from adipocytes they do not exert 
CNS-mediated effects which are functionally relevant, it does however complicate our 
understanding of the underlying mechanisms. Furthermore, while some adipokines have been 
shown to have physiological effects when injected directly into the CNS, evidence for their 
transport across the BBB may not have been conclusively proven making the physiological 
significance of some of the findings unclear; at least under non-pathologic conditions when the 
BBB is fully intact and functioning normally. 
In the following sections we will encounter some of these issues as we review the literature 
around the CNS targets of some other adipokines that have been shown to have CNS-mediated 
effects on physiology. Much of this section will be focused on the CNS-mediated effects of these 
other adipokines on glucose and energy homeostasis, as this has been the main focus of much of 
the published work; however, other important physiological and pathological are also likely to be 
regulated by these proteins. 
 
Resistin 
Resistin, so-called due to its ability to induce insulin resistance, is a 12.5 kDa cysteine-rich 
polypeptide hormone (of the resistin-like molecule family) which was discovered as part of a study 
to identify adipose-derived factors that are regulated by TZD anti-diabetic drugs (540). Resistin is 
synthesized (during adipogenesis) and secreted from white adipocytes in rodents (540); however, 
in humans monocytes and macrophages are believed to be the main source (448, 503), 
highlighting important species differences. Elevated levels of resistin are reported in diet-induced 
and genetically obese mice (540) with insulin and glucose both proposed to mediate the 
nutritional regulation of resistin mRNA in WAT and circulating serum levels in rodents (473). In 
obese humans, resistin serum levels display a positive correlation with alterations in BMI, body 
fat, circulating insulin and mean glucose amongst others (21, 473). However, it should be stated 
that a minority of studies have failed to identify a relationship between resistin and known 
markers of insulin resistance in humans and as such it remains controversial (291, 346, 577). Of 
interest, in rodents resistin mRNA has also been detected in BAT, pancreatic β-cells, skeletal 
muscle tissue, kidney (424) and brain (47, 602). 
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CNS-mediated effects of resistin on glucose and energy homeostasis 
Resistin is hypothesized to play a role in obesity-induced insulin resistance and T2D (119, 519) 
as immunoneutralization of endogenous resistin in vivo enhances insulin-stimulated glucose 
uptake and improves insulin sensitivity in high-fat diet-induced obese mice (540). In contrast, in 
lean mice, intraperitoneal administration of recombinant resistin results in glucose intolerance and 
insulin resistance (540). These findings are further supported by work in mice  indicating that 
genetic deletion of resistin in both wild-type and leptin-deficient ob/ob animals improves glucose 
homeostasis (463), while transgenic overexpression of resistin in adipose tissue induces insulin-
resistance (445). 
How resistin mediates obesity-induced insulin resistance is not well understood, in part due to the 
fact that the target receptor has not yet been identified (22, 113). However, evidence suggests 
that central administration of leptin is sufficient to decrease WAT resistin mRNA levels and 
improve insulin sensitivity in ob/ob mice (20) providing a potential functional link between the two 
adipokines. Resistin-associated impairment in insulin sensitivity occurs primarily in the liver via 
modulation of hepatic gluconeogenesis (26, 472). Evidence suggests that this effect of may be 
mediated, at least in part, via the CNS. Hepatic insulin resistance can be induced by acute central 
infusion of resistin and is linked to glycogenolysis, and induction of cytokine and SOCS3 
expression in the liver. These effects are thought to be mediated via the hypothalamus and 
depend on intact NPY Y1 signaling (414, 523). In rodents, chronic central infusion of resistin 
promotes inflammation and insulin resistance through hypothalamic TLR4 signal transduction in 
vivo, leading to activation of JNK and p38/MAPK signaling pathways, which upregulates IL-6, 
SOCS3 and PTP1B (47). This finding indicates that inflammation is a key mechanistic event 
mediating resistin-induced insulin resistance. Evidence also suggests that chronic central infusion 
of resistin is sufficient to down impair adiponectin and fibroblast growth factor 21 (FGF21) 
signaling in the brain and periphery but this appears to be secondary to the inflammatory effects 
on chronic central infusion of resistin as the effect is lost following inhibition of TL4R signaling 
(46). 
In addition to having an effect on glucose homeostasis, evidence exists for an effect of centrally 
administered resistin on energy homeostasis in rodents. Intracerebroventricular administration of 
10µg resistin acutely suppresses fasting-induced and typical day-time food intake in fed rats (567, 
585). In this study, intracerebroventricular resistin was found to induce c-FOS and SOCS3 in the 
ARC suggesting a hypothalamic site of action. Indeed, centrally administered resistin prevents 
fasting-induced increases in orexigenic AgRP and NPY mRNA expression, whilst also decreasing 
anorexigenic CART mRNA expression in the ARC (585). Interestingly, chronic 
intracerebroventricular infusion of resistin into diabetic rats (that had undergone pancreatectomy) 
has little effect on food intake or body weight; however, resistin is able to attenuate the effects of 
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leptin on these parameters when the two were co-infused providing further evidence supporting a 
potential functional interaction between the two peptides (447). Central administration of resistin 
has also been shown to impact energy expenditure via modulation of sympathetic nerve activity: 
increasing skeletal muscle (lumbar) and decreasing brown adipose tissue sympathetic nerve 
activity (as first demonstrated in rats) potentially implicating resistin, via its effects on sympathetic 
nerve activity, in metabolic dysfunction seen in obesity and diabetes (328). 
  
Other CNS-mediated effects of resistin on physiology 
In addition to impacting glucose and energy homeostasis, other CNS-mediated effects of resistin 
have also been reported in animal models. These include a role for resistin in regulating pituitary 
somatotrope cell functions (487), and obesity-induced hypertension, as central resistin was found 
to enhance renal sympathetic nerve activity (327); thus, impacting salt and water balance (22).  
Intriguingly, in contrast to mice, in human-derived adipocytes resistin is barely detectable, with 
mRNA levels actually reported to be higher in monocytes and macrophages (448, 503). Of note, 
high concentrations of leptin and insulin upregulate resistin mRNA and protein secretion in 
human-derived peripheral blood monocyte-enriched mononuclear cells in vitro (574). In human 
obesity, the main source of resistin appears to originate from infiltrating macrophages found in 
visceral WAT (132). Indeed, a role for resistin in inflammation in immune cells has been 
proposed, as resistin stimulates proinflammatory TNFα and IL-6 expression in human blood 
monocyte-enriched mononuclear cells and in both human and mouse macrophages, the latter via 
NFκB signaling (58, 521, 574). 
Resistin has also been implicated in the pathology of a number of conditions characterized by 
inflammation. For example, people suffering from acute inflammatory disease display higher 
serum resistin levels (538) and others have suggested a pathological role of resistin in traumatic 
brain injury (72). Resistin could also potentially be an etiological factor in cardiovascular disease 
(78, 479), as exogenous resistin has been demonstrated to activate vascular endothelial cells 
(586) and promote the proliferation of smooth muscle cells (81). 
 
Challenges in understanding the biology of resistin 
Overall, our current understanding of the role of resistin in glucose homeostasis, inflammation 
and vascular disease is complicated by several findings: 1) resistin mRNA levels do not always 
complement the changes observed in serum resistin levels in models of obesity/T2D; 2) the 
expression of resistin appears to be differentially regulated both between species (humans vs. 
rodents) and within tissues (with respect to distribution profiles) (448, 503, 540), and 3) the 
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receptor mediating the physiological effects of resistin remains to be determined. Studies on 
resistin demonstrate its ability to activate a variety of signaling cascades; thus, it may potentially 
interact with one than one receptor, depending on target tissue and cell type (47, 81, 326, 327, 
487). 
Resistin mRNA is detected in rodent brain, in hypothalamic nuclei such as the ARC, which could 
be a site of endogenous resistin production (47, 602). In humans resistin has been detected in 
CSF (325), which may originate from within the brain or from peripheral resistin crossing the 
through the BBB. The finding of a CNS source of resistin means that many of the CNS-mediated 
effects of resistin described above could be as a result of the centrally-derived and not WAT-
derived peptide pool. This further complicates our current understanding of the physiological role 
of this adipokine. Further studies examining the effect of selective loss of CNS compared with 
peripheral resistin pools could help elucidate this.  
 
Apelin 
The peptide apelin is an endogenous ligand of the class A G protein-coupled APJ receptor (556), 
which is reported to share most homology (~30-40%) with the angiotensin II receptor (428). 
Apelin and the APJ receptor are widely expressed both in the periphery and CNS in humans and 
rodents (342, 392, 394, 461), including in adipocytes (62).  Apelin is obtained from a 77 amino 
acid preproprotein (preproapelin), enzymatically cleaved to produce bio-active endogenous C-
terminal fragments including, apelin-13 (and its pyroglutamylated form, pGlu-apelin-13), apelin-
17, apelin-36 and “synthetic” apelin-12 (141, 172, 231). The species-specific distribution of long 
(apelin-36) and short (for example, apelin-13) forms of apelin has been shown to vary in different 
tissues ((303), for review see (457)). Recently, another endogenous peptide, Toddler/ELABELA, 
was also found to activate the APJ receptor and was shown to be important for embryonic 
development in zebrafish (112, 451). Collectively, apelin-APJ signaling is relatively diverse, as 
various molecular forms of apelin can bind to and activate APJ receptors, recruiting different G 
proteins associated with a variety of intracellular cascades in a tissue- and cell-specific manner 
(427). Masri et al., (386) have demonstrated that the APJ receptor is differentially desensitized as 
a result of preferential G-protein coupling by apelin fragments. 
 
CNS-mediated physiologic effects of apelin on energy homeostasis 
Due to the widespread mRNA expression of mammalian apelin and the APJ receptor, associated 
functional effects have been demonstrated in the periphery and CNS (88). In 2005, apelin was 
identified as an adipokine, shown to be expressed and secreted from human and mouse cultured 
adipocytes, with increased expression seen during adipocyte differentiation (62). Nutritional 
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status exerts an important influence on apelin expression in adipocytes, with fasting resulting in a 
strong inhibition, whilst refeeding reversed this effect in vivo; in fact, apelin expression is directly 
regulated by insulin through PI3K, protein kinase C (PKC) and MAPK stimulation, with elevated 
apelin plasma levels and increased apelin mRNA expression reported in adipocytes from obese 
hyperinsulinemic mice (62). Importantly, upregulation of  adipocyte apelin levels in obesity is only 
seen when the obesity is associated with hyperinsulinemia, indicative of insulin, rather than 
obesity per se, being a potent regulator of apelin expression (62, 92). Of interest, TNFα has also 
been shown to induce the expression of apelin in adipose tissue via PI3K, JNK and MAPK1/2 
signaling (138). Overall, apelin appears to exert a direct anti-diabetic effect, playing an important 
role in glucose homeostasis (91, 97). In humans, elevated levels of plasma apelin were reported 
in morbidly obese and/or in type 2 diabetic subjects (253, 360), although not all studies report a 
positive correlation between circulating levels of apelin and BMI, highlighting once more that 
obesity alone does not determine circulating apelin levels (51, 91). More recently, it was shown 
that the intracerebroventricular injection of a high dose of pGlu-apelin-13 was capable of 
controlling hepatic glucose metabolism via activation of the sympathetic nervous system, the 
effect of which was dependent on the elevated production of hypothalamic reactive oxygen 
species (ROS) by apelin (158). Importantly, these authors concluded that increased levels of 
central apelin in obese/diabetic mice appears to actually contribute to a type 2 diabetic state, as 
chronic blockade of central apelin with the APJ receptor antagonist F13A, resulted in an 
improvement in the regulation of glucose homeostasis during the diabetic state in high-fat fed 
mice.  
A controversial role of apelin and the APJ receptor in the central regulation of food intake exists. 
The intracerebroventricular administration of pGlu-apelin-13 in fed rats was shown to have no 
effect on food intake, with a significant increase in food intake seen during the subjective day in 
fasted rats only at the highest dose tested (551). In another study, it was reported that 
intravenous injection of apelin-13 did not alter food intake in fed or fasted rats; however, a 
decrease in food intake was shown after intracerebroventricular infusion of apelin-13 in fed and 
fasted rats (546). In addition, the central administration of apelin-12 was found to reduce food 
intake during the subjective night period in rats (2-4 hours post-infusion) and actually stimulated 
feeding in fed rats during the subjective day, but only at the highest dose and only in some rats 
(430). Thus, the effectiveness of apelin may depend on the level of satiety of the animal, the time 
of day, the dose and route of administration, and the apelin form used. The link between body 
weight and responsiveness to apelin was explored by Clark et al., (116), who showed that 
intracerebroventricular infusion of apelin-13 (at the end of the subjective day) decreased food 
intake in diet-induced obese rats fed a control diet, but this effect was absent in diet-induced 
obese rats fed a high-fat diet. This insensitivity to apelin was associated with the downregulated 
mRNA expression of hypothalamic APJ receptors by apelin in specifically the diet-induced obese 
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rats fed a high-fat diet. Of interest, the chronic (10 day) infusion of apelin-13 into the third 
ventricle in mice resulted in an increase in several parameters measured, including food intake 
and body weight (these effects were indistinguishable from saline-treated controls after day 8), 
with secondary effects noted such as increased locomotor activity, especially during the animal’s 
active phase, which was accompanied by an increase in body temperature during this period 
(580). Higuchi et al., (255) demonstrated that chronic (14 day) intraperitoneal injection of apelin-
13 in normal and high-fat fed mice resulted in a decrease in weight of white adipose tissue, with 
no apparent effect on food intake. This apelin-induced decrease in body adiposity was proposed 
to be mediated by an increase in energy expenditure, as apelin treatment was associated with the 
increased mRNA and protein expression of UCP1 and UCP3 in brown adipose tissue and 
skeletal muscle respectively (255). Furthermore, it is hard to exclude central regulation of energy 
expenditure by apelin as brain areas, such as the hypothalamus and sympathetic nerve activity 
are known to regulate UCP1 in brown adipose tissue (25, 504). Indeed, recent evidence has 
implicated apelin-APJ signaling in the enhancement of brown adipogenesis and adipose tissue 
browning, involving PI3K/Akt and AMPK signaling and relief from the known inhibitory effects of 
TNFα on brown adipogenesis (562). The recent report by Drougard et al., (159) showed that 
chronic intracerebroventricular injection of a high dose of apelin-13 in normal mice was enough to 
induce the hypothalamic upregulation of proinflammatory markers, in accordance with the 
previously reported effect of apelin in vitro, in microglial BV2 cells (103). In addition, this treatment 
in mice was associated with no change in either body weight or food intake, yet a decrease in 
thermogenic capacity and energy expenditure was reported and found to be associated with the 
decreased mRNA expression of peroxisome proliferator-activated receptor 1 alpha (PGC1α), PR 
domain containing 16 (Prdm16) and UCP1 in brown adipose tissue (159). These latter findings 
are suggestive of decreased mitochondrial biogenesis and attenuated activity and function of 
brown adipose tissue. Of note, the application of apelin-13 in hypothalamic slices was found to 
stimulate hypothalamic POMC-positive neurons in vitro (159), Intriguingly, within the arcuate 
nucleus of the hypothalamus, ~90% of apelin-positive neurons appear to be POMC-positive, with 
APJ receptors found to be expressed in ~50% of POMC-positive neurons (477). In line with these 
findings, Lee et al., (343) previously demonstrated that the application of apelin-13 in 
hypothalamic slices containing the arcuate nucleus enhanced the intrinsic excitability of identified 
POMC-EGFP neurons through Gβγ activation of phospholipase C (PLC) -β signaling and 
inhibition of M-currents via the downstream inactivation of KCNQ channels. It is interesting that 
Drougard et al., (159) saw no effect of apelin on food intake, yet also reported an enhancement of 
POMC activity by apelin. Such findings highlight the proposed functional heterogeneity of 
hypothalamic POMC neurons, with distinct subpopulations responsible for different aspects 
related to the regulation of food intake and energy metabolism (531). 
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Apelin and cognitive function 
A role for apelin-13 in anxiety (559) and cognition has recently been addressed. With respect to 
cognition, post-training intracerebroventricular infusion of apelin-13 in mice trained in the novel 
object recognition memory task was shown to induce impairments in both the formation of short-
term memory and consolidation of long-term memory, with no apparent impairment seen in 
acquisition of the memory per se (242). Such findings are in line with the known expression of 
apelin and the APJ receptor in brain regions associated with learning and memory processing 
(394). However, apelin and the APJ receptor are also expressed in brain areas related to the 
stress response (427). Indeed, apelin plays a role in the regulation of the hypothalamic-pituitary-
adrenal (HPA) axis, as central administration of pGlu-apelin-13 increased plasma 
adrenocorticotropic hormone (ACTH) and corticosterone levels, with findings from hypothalamic 
extracts demonstrating that this effect of apelin could be mediated through apelin stimulated 
release of arginine vasopressin (AVP) and corticotrophin releasing hormone (CRH) (551). 
Furthermore, the recent report by Li et al., (358) demonstrated that in stressed rats which 
displayed depressive-like and cognitive impairments, the repeated intracerebroventricular infusion 
of apelin-13 resulted in an anti-depressant-like phenotype, as evaluated in the forced swim and 
learned helplessness tests. In addition to this, apelin-13 was able to reverse the memory 
impairment seen in the novel object recognition test in stressed rats, the mechanism of which 
involved PI3K and MAPK1/2 activation. Thus, apelin-APJ signaling may prove to be a useful 
target for the treatment of depression.    
 
Other CNS mediated effects of apelin 
Functionally, apelin has been shown to be important in cardiovascular functions, regulating both 
blood pressure and vascular tone via nitric oxide signaling (292, 342, 557) and it also displays 
angiogenic properties (298). A pathophysiological role of apelin-APJ signaling has been 
described in human cardiovascular disease (458); however, neuroprotective effects of apelin-APJ 
have also been described in a model of ischemic/reperfusion injury in rats (631). In line with this, 
in the CNS, the intracerebroventricular infusion of apelin-13 was found to be neuroprotective 
suppressing neuroinflammation in an experimental rat model of ischemic stroke (612). In addition, 
apelin has been shown to play a role in the central control of body fluid homeostasis, involving 
modulation of AVP release by apelin at the level of the hypothalamus (141, 478, 485).  
 
Does adipocyte-derived apelin exert physiological effects via the CNS? 
Although, peripheral administration of apelin-12 increased c-FOS immunoreactivity in a number of 
brain areas including the PVH, LHA, LPB, NTS and DMX (552), it should, however, be noted that 
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apelin transport across the BBB has not as of yet been conclusively demonstrated (619). As 
such, it is unclear whether adipocyte-derived apelin exerts any CNS mediated effects on 
physiological processes, particularly in the context of obesity /hyperinsulinemia when adipose 
tissue levels are elevated (62).  Further study examining the relative impact of CNS compared 
with adipose apelin deficiency on normal physiology and pathology may help to address this 
question. 
 
Visfatin 
Visfatin, a 52 kDa protein, first identified as an adipokine in 2005 was shown to be predominately 
produced and secreted by human and mouse abdominal visceral fat, with plasma levels positively 
correlating with both the amount of visceral (but not subcutaneous) fat in humans and the 
development of obesity in mice (204). Visfatin was found to correspond to pre-B-cell colony-
enhancing factor (PBEF) (204), a protein with cytokine activity mainly expressed in lymphocytes 
and other cells found in human bone marrow, muscle and liver (499), also recognized for its 
nicotinamide phosphoribosyltransferase (NAMPT) activity (488). For clarity, visfatin, PBEF and 
NAMPT are acknowledged as the same protein (135, 276, 532). Visfatin/NAMPT exists in 2 forms 
in mammals: the intracellular form which is accepted to have nicotinamide adenine dinucleotide 
(NAD
+
) biosynthetic enzyme function in cellular redox reactions, and an extracellular form the 
function of which remains controversial, with various attributed roles including as an insulin-
mimetic adipokine, proinflammatory cytokine and NAD biosynthetic enzyme (210), all of which will 
be discussed below. A potentially important role of visfatin in physiology and/or development is 
supported by the finding that germ-line deletion of the visfatin gene results in embryonic lethality 
in homozygous deficient animals (204). 
Effects of visfatin on glucose and energy homeostasis 
Initial findings by Fukuhara et al., (204) demonstrated a glucose-lowering (insulin-mimetic) effect 
of visfatin through the acute intravenous injection of recombinant visfatin in wild type mice, 
insulin-resistant obese (KKAy) mice and in streptozotocin-induced models of diabetes in mice. 
Indeed, chronic administration of recombinant visfatin via adenoviral vector delivery in wild type 
and KKAy mice also resulted in a lowering of plasma glucose (and insulin) levels. Although 
animals homozygous for a deletion in visfatin (visfatin
-/-
 mice) died during embryogenesis, 
animals heterozygous for the deletion (visfatin
+/-
 mice) showed a seemingly normal metabolic 
phenotype (including body weight and growth rate) except for mild elevations in circulating 
glucose and slightly impaired glucose clearance in a glucose tolerance test (204).  Furthermore, 
in in vitro studies in 3T3-L1 adipocytes and L6 myocytes, visfatin (like insulin) was found to 
stimulate glucose uptake, whilst also suppressing glucose release in H4IIEC3 hepatocytes (204). 
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Visfatin was found to bind the insulin receptor (at a different site to that of insulin) and activate 
downstream insulin signaling, involving the phosphorylation of the insulin receptor, IRS-1 and 
IRS-2 and activation of PI3K/Akt and MAPK signaling in cultured adipocytes, myocytes and 
hepatocytes (204). Yet, the binding of visfatin to the insulin receptor was later discovered to be 
batch-dependent (of purified recombinant visfatin protein preparation), resulting in the subsequent 
retraction of the original article (203). Nonetheless, findings from other groups reported similar 
insulin mimetic effects of visfatin in cultured osteoblasts (611) and a possible interaction between 
visfatin and the insulin receptor to induce glucose uptake in cultured kidney mesangial cells (533). 
In contrast, a study by Revollo et al., (482) provide strong evidence against an insulin-mimetic 
action of visfatin instead proposing that the effects of visfatin on glucose homeostasis are 
mediated by impacting NAD
+
 biosynthesis and subsequent regulation of insulin secretion from 
pancreatic β-cells.  
Elevated plasma visfatin levels have been reported in obese and non-obese patients with T2D 
(104, 171) and in both overweight and obese patients associated with MetS (192). However, the 
relationship between visfatin and metabolic disorders remains controversial (50, 286, 439), for 
review see (210)). A potential role for visfatin in the pathogenesis of cardiovascular disease 
associated with obesity and T2D has been proposed based on evidence of effects of visfatin on 
vascular inflammation (4, 136). Indeed, visfatin levels and/or mRNA expression in humans 
appear to be elevated in several other inflammation-associated conditions including, chronic 
obstructive pulmonary disease (363), rheumatoid arthritis (70, 391, 436) and osteoarthritis (105, 
391).  
The presence of visfatin in the CNS of rats was first demonstrated in 2003 (315) and some years 
later visfatin was also identified in human CSF (239). First, the previous observation that elevated 
plasma visfatin levels were associated with increasing BMI and body fat mass in human subjects 
was also confirmed by Hallschmid et al., (239); second, they reported the presence of visfatin in 
human CSF (at ~10% to that of plasma levels); third, a decrease in CSF visfatin levels was found 
to be related to the incremental rise in several factors including, plasma visfatin levels, BMI, body 
fat mass and insulin resistance in humans subjects. The authors concluded that since only body 
fat mass (adiposity) was independently associated with CSF visfatin levels, the decrease in CSF 
visfatin levels observed may reflect an impaired transport of visfatin across the BBB in obesity 
and/or may contribute to obesity-related pathologies (239). To date, the direct action of visfatin at 
the level of the BBB has not yet been explored yet given its impact of vascular endothelial cells 
(described above) (4, 136) a potential proinflammatory effect on BBB endothelial cells could 
reasonably be postulated. 
It is currently unknown whether circulating visfatin can enter the CNS and moreover, whether or 
not it can be directly secreted from specialized CNS sites. Nevertheless, a possible role for 
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visfatin in the central regulation of food intake has been indicated by a study performed in chicks. 
Intracerebroventricular infusion of recombinant human visfatin in chicks induced an increase in 
food intake, with associated changes in neuronal activity (as reflected by increased c-FOS 
expression) in the lateral hypothalamus (118). Recent work in mammals has demonstrated that 
chronic central infusion of visfatin in diabetic rats improves hypothalamic insulin (but not leptin) 
signaling through Akt phosphorylation, with no other long-term effects observed with regards to 
body weight, visceral fat accumulation or energy expenditure (309). This improvement in glucose 
homeostasis in diabetic rats was found to involve the potentiation of glucose-stimulated insulin 
secretion, rather than an improvement in insulin sensitivity per se and was associated with 
increased pancreatic β-cell mass (309). The authors proposed a CNS-to-periphery signaling 
mechanism of visfatin, transmitted via the autonomic nervous system, since the chronic infusion 
of central visfatin did not alter serum visfatin levels. Recently, it was demonstrated that the NAD
+
-
dependent deacetylase sirtuin-1 (SIRT1) could promote the release of the extracellular form of 
NAMPT (visfatin) by deacetylating intracellular NAMPT at lysine 53 in adipocytes, in turn, 
enhancing the activity of extracellular NAMPT (622). In addition, this peripherally-derived NAMPT 
was shown to influence hypothalamic NAD
+
-SIRT1 signaling and physical activity in mice, 
suggestive of the important role of adipose tissue in modulating systemic NAD
+
 biosynthesis 
which may be key in the maintenance of metabolic homeostasis (622).  
 
Adipocyte-derived cytokines 
As adipocyte-derived cytokines may not be adipokines in the purest sense of the definition, a 
conscious decision has been made to keep this section brief. Additionally, due to the highly 
heterogeneous nature of adipose tissue: a mixture of adipocytes, preadipocytes, mesenchymal 
stem cells, fibroblasts, endothelial and immune cells; it can be experimentally challenging to 
accurately identify which cell type(s) within adipose tissue are producing cytokines (and in what 
proportions) under basal and pathological conditions. However, as adipocytes produce cytokines 
which undoubtedly have critical roles in physiology and pathology, it was felt that they should not 
be completely omitted.  
 
Proinflammatory cytokines and CNS regulation of energy homeostasis  
Obesity is now well accepted to be a state of chronic low-grade inflammation, characterized by 
the synthesis of proinflammatory cytokines, such as TNFα and IL-6, from both adipocytes and 
immune cells found within adipose tissue (196, 267, 598). The immunological changes in adipose 
tissue associated with obesity are diverse and wide-ranging with changes in immune cell 
populations in adipose tissue from both the innate and adaptive branches of the immune system 
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(388). The dysregulation of pro- versus anti-inflammatory cytokine production in obese adipose 
tissue contributes to various aspects of the metabolic syndrome (145, 437). Indeed, obesity-
related inflammation is associated with both peripheral and central leptin and insulin resistance 
(43, 196).  
In addition to inducing inflammation in adipose tissue, obesity also leads to elevations in 
proinflammatory cytokines (143, 561) and activation of glial cells (75, 265, 561) in the CNS. While 
the hypothalamus is the area of the brain predominantly studied in this regard (75, 265, 561) 
evidence also indicates that other brain sites including the hippocampus are impacted (75, 228, 
456). Indeed, in neurons and astrocytes the NFκB pathway, which is known to be critical in 
mediating inflammatory signaling, is important for the central regulation of energy homeostasis 
(74, 635). Furthermore, in a rodent model of obesity, inhibition of TNFα signaling in the 
hypothalamus by infusion of a neutralizing antibody is sufficient to improve peripheral insulin 
sensitivity (17, 402) and the thermogenic capacity of BAT (17); thus, demonstrating that 
modulation of inflammatory signaling in the CNS can induce changes in the function of peripheral 
organs and potentially contribute to the pathology of the disease. It is important to note that in 
these studies it is not known whether inhibiting inflammatory signalling in the CNS alters 
physiology solely by impacting obesity-associated CNS-derived inflammation, CNS-actions of 
adipocyte/adipose tissue-derived cytokines or a combination of both. 
The cellular origin of the proinflammatory cytokines produced in the CNS associated with obesity 
remains to be fully determined, but is likely to be a combination of glial (astrocytes, tanycytes, and 
microglia) and neuronal sources. Regardless of the cell(s) producing them, proinflammatory 
cytokines likely mediate their downstream effects via autocrine and paracrine actions on different 
cell types. CNS-derived cytokines have extensive roles in modulation of physiology and 
pathophysiology but as the focus of this article is the CNS actions of adipokines (which may 
include cytokines derived from adipocytes) we feel a discussion of this is beyond the remit of this 
article and has recently been extensively reviewed elsewhere (42).  
The dissection of central versus peripheral actions of adipocyte-derived cytokines is a critical one 
for our understanding of their physiological actions, particularly in relation to the pathophysiology 
of obesity-associated inflammation. What currently is not clear is the relative time course of CNS 
and adipose tissue inflammation in response to obesogenic stimuli such as high-calorie diets: 
does adipose tissue inflammation promote CNS inflammation via the action of adipose-derived 
cytokines in the CNS or does CNS inflammation promote inflammatory changes in WAT? 
Alternatively, do they arise simultaneously in response to common stimuli? Research in rodent 
models indicates that hypothalamic inflammation arises after only 24h of exposure to an 
obesogenic high-fat diet (74, 561), which in the 2012 study of Thaler and colleagues (561) was 
found to be prior to the onset of adipose tissue inflammation. This suggests that hypothalamic 
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inflammation may be part of a homeostatic response to help restore energy homeostasis via 
modulation of the hypothalamic neuronal circuitry. Indeed, this is supported by data indicating that 
inhibition of NFκB signaling in astrocytes (a type of glial cell) was sufficient to acutely alter the 
feeding response to a high-fat diet (74) suggesting that inflammatory signaling in the brain is 
important for homeostatic regulation in this context. 
Regardless of which arises first, CNS or WAT inflammation, it is highly likely that in obesity the 
presence of inflammation in both these organs perpetuates the inflammatory state in the other by 
promoting dysregulation of normal physiological mechanisms within these tissues. However, 
further work is required to fully clarify the relative contribution of each. In a 2010 review, Banks & 
Erikson summarized a number of potential mechanisms by which a circulating cytokine can 
influence CNS function: 1) vagal or other afferent nerve stimulation; 2) release from immune cell 
transport; 3) stimulation through circumventricular organs; 4) direct passage; and 5) self-
stimulated release from CNS pools (31). Importantly, the CNS itself can act as an endocrine 
organ (28), secreting bio-active substances including centrally-derived TNFα and IL-6 which can 
cross the BBB to enter the blood (101). Furthermore, the BBB itself is also capable of secreting 
neuroimmune-related substances, both constitutively and when induced to do so by CNS or 
peripheral signals (31).  
The BBB is critical for CNS function and protects the brain from acute changes in the periphery 
including infectious agents, toxins and acute nutritional variations (1). Under physiological 
conditions, some peripheral factors cross the BBB (depending on their polarity and size) in a 
regulated manner; however, when BBB integrity is disrupted by damage, inflammation and/or 
oxidative stress (444) this regulation is impacted. Indeed, a positive correlation between 
obesity/diabetes and increased risk of developing dementia, cognitive impairments and/or 
neurodegenerative diseases has been established and adipokine dysregulation may play a key 
role in the development of such disorders (16, 308, 396, 444). 
  
Conclusion 
The discovery of adipokines has fundamentally changed our understanding of endocrinology. 
Through their actions in the CNS, adipokines can influence numerous aspects of physiology as 
diverse as cognition, reproduction and cardiovascular function. In particular, leptin, with its 
widespread receptor distribution in the CNS has a neuromodulatory effect on many key neural 
pathways, including autonomic, mesolimbic dopamine, neuroendocrine, and vagal circuits. A 
challenge in studying CNS targets of adipokines is that much of the work to date has been carried 
out in animals (principally rodents) and its transferability to humans is not easily determined. 
Perhaps by virtue of being the first to be discovered, leptin has been shown to have the most 
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wide-ranging functions of all adipokines. However, as new adipokines are continuously being 
identified, our understanding is constantly developing. Recent work has highlighted that in 
addition to neurons, non-neuronal cells are also important targets for the actions of adipokines 
(23, 272, 310) and this remains an emerging area of study, as indeed is the role of non-neuronal 
cells in the regulation of physiological processes. 
Despite our growing knowledge and appreciation of the importance of adipokines in modulating a 
range of physiological functions, to date, this large body of work has only led to the development 
of one novel Food and Drug Administration (FDA) approved therapeutic application in human 
disease: the use of a leptin analog to treat generalized lipodystrophy (524). Perhaps the Holy 
Grail of pharmacological therapies would be the development of the elusive brain permeable 
leptin-sensitizing agent that could help fight obesity by increasing CNS sensitivity to the patient’s 
high circulating levels of the hormone. Currently, our understanding of how leptin and other 
adipokines enter the CNS to exert their effects is somewhat incomplete. Investigating this further, 
whilst advancing our fundamental knowledge of the actions of adipokines in the CNS, will 
undoubtedly lead to the development of novel therapeutic agents to tackle human disease. 
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Tables 
 
Table 1: List of abbreviations 
Abbreviation Definition 
Aβ Amyloid beta 
ACC Anterior cingulate cortex  
ACE Angiotensin-converting enzyme  
ACTH Adrenocorticotropic hormone  
AD Alzheimer’s disease 
AgRP Agouti-related protein 
AHA Anterior hypothalamic area 
AMPK AMP-activated protein kinase  
α-MSH  Alpha melanocyte stimulating hormone 
AP Area postrema 
APP/PS1 Amyloid precursor protein/presenilin 1 
ARC Arcuate nucleus of the hypothalamus 
ATP Adenosine triphosphate 
AVP Arginine vasopressin  
BAT Brown adipose tissue 
BBB Blood brain barrier 
BMI Body mass index 
CamKII Calcium calmodulin-dependent protein kinase II 
CART Cocaine- and amphetamine-regulated transcript 
CCK Cholecystokinin 
CNS Central Nervous System 
CRH Corticotrophin releasing hormone  
CRR Counter-regulatory response 
CSF Cerebral-Spinal Fluid 
D2 Deiodinase type II  
DBP Diastolic blood pressure 
DMH Dorsomedial nucleus of the hypothalamus 
DMX Dorsomotor nucleus of the vagus  
DREADDs Designer Receptors Exclusively Activated by Designer Drugs 
DVC Dorsal vagal complex  
EGFP Engineered green fluorescent protein 
eNOS Endothelial nitric oxide synthase  
ER Endoplasmic reticulum 
ERK Extracellular signal-regulated kinases 
FDA Food and Drug Administration  
FGF1 Fibroblast growth factor 1  
FGF21 Fibroblast growth factor 21 
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FOXO1 IRS-Akt-forkhead box protein 01  
FSH Follicle–stimulating hormone  
GABA Gamma-aminobutyric acid 
GFAP Glial-fibrillary acidic protein  
GH Growth Hormone 
GI Gastrointestinal 
GLP-1 Glucagon like peptide-1 
GAD67 Glutamic acid decarboxylase 67  
GnRH Gonadotrophin-releasing hormone  
HMW High molecular weight multimers 
HPA Hypothalamic-pituitary-adrenal  
HPG Hypothalamic-pituitary-gonadal 
HPT Hypothalamus pituitary thyroid 
ICV Intracerebroventricular 
IRS Insulin receptor substrate 
Jak Janus kinase 
JNK c-Jun N-terminal kinase  
KA Kainic Acid 
LH Luteinizing hormone 
LHA Lateral hypothalamic area 
lPB Lateral parabrachial nucleus  
IFN Interferon 
LTD Long-term depression  
LTP Long-term potentiation 
MAPK Mitogen-activated protein kinase 
MC3R Melanocortin-3 receptor 
MC4R Melanocortin-4 receptor 
MCAO Medial cerebral artery occlusion  
ME Median eminence 
MCH Melanin-concentrating hormone 
MCI Mild cognitive impairment  
NAMPT Nicotinamide phosphoribosyltransferase  
NAD Nicotinamide adenine dinucleotide  
mPOA Median preoptic area 
mTOR Mechanistic target of rapomycin 
NFkB Nuclear factor kappa B 
NMDA N-methyl-D-aspartate  
NPY Neuropeptide Y 
NTS Nucleus of the solitary tract 
ob Obese gene 
Ob-R Leptin receptor 
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OST-PTP Osteotesticular protein tyrosine phosphatase 
PACAP Pituitary adenylate cyclase-activating polypeptide 
PBA 4-phenyl butyrate  
PBEF pre-B-cell colony-enhancing factor 
PBN Parabrachial Nucleus 
PGC1α Peroxisome proliferator-activated receptor 1 alpha  
PI3K Phosphoinositide 3-kinase 
PIO Pioglitazone 
PKC Protein kinase C 
PLC Phospholipase C 
POA Preoptic area 
POMC Proopiomelanocortin 
PPAR Peroxisome proliferator-activated receptor 
PMv Ventral premammillary nucleus 
PrRP Prolactin-releasing peptide  
proTRH Pro-thyrotropin-releasing hormone  
pSTAT Phosphoylated signal transducer and activator of transcription 
PTP1B Protein-tyrosine phosphatase 1B 
PVH Paraventricular nucleus of the hypothalamus 
RAS Renin-angiotensin system  
RER Respiratory exchange ratio  
ROS Reactive oxygen species 
rPA Rostral raphe pallidus 
RVLM Rostral ventrolateral medulla 
scWAT Subcutaneous white adipose tissue 
SF-1 Steroidogenic factor 1 
SFO Subfornical organ  
SIRT1 Sirtuin-1  
SHP2 Src-homology 2 domain-containing phosphatase 2 
SHP2 Src-homology 2 domain-containing phosphatase 2 
SNP Single nucleotide polymorphisms  
SOCS Suppressor of cytokine signalling 
SON Supraoptic nucleus 
SREBP2 Sterol-regulatory element binding protein 2  
STAT Signal transducer and activator of transcription 
T1D Type-1 diabetes 
T2D Type-2 diabetes 
T3 Triiodothyronine 
T4 Thyroxine 
TH Tyrosine hydroxylase 
TLR4 Toll-like receptor 4  
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TNFα Tumor necrosis factor alpha 
TRH Thyrotropin-releasing hormone  
TSH Thyroid-stimulating hormone  
TUDCA Tauroursodeoxycholic acid  
Tyr Tyrosine 
TZD Thiazolidinedione 
UCP1 Uncoupling protein 1 
UCP2 Uncoupling protein 2 
VAD Vascular dementia  
VLM Ventrolateral medulla 
VMH Ventromedial nucleus of the hypothalamus 
VTA Ventral tegmental area  
WAT White adipose tissue 
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Table 2: Mammalian CNS Leptin Receptor Distribution 
CNS expression site Reference Cell type 
Hypothalamus 
-Arcuate Nucleus (ARC) 
-Dorsal Medial (DMH) 
- Lateral Hypothalamic area (LHA) 
-Median Eminence (ME) 
-Paraventricular Nucleus (PVH) 
-Ventromedial Nucleus (VMH) 
-Ventral Premammillary Nucleus (PMv) 
-Median preoptic area (mPOA) 
 
Mercer et al., 1996 (398) 
Schwartz et al., 1996 (507) 
Guan et al., 1997 (226) 
Elmquist et al., 1998 (180) 
Patternson et al.,  2011 (449) 
 
POMC neurons (108) 
NPY/AgRP neurons (397) 
Neurotensin neurons (353) 
CART neurons (176) 
Galanin neurons (339) 
TRH neurons (247) 
Astrocytes (272) 
Tanycytes (23) 
GABAergic neurons (587) 
Prolactin-releasing peptide neurons (PrRP) (155) 
Cortex Mercer et al., 1996 (398)  
Hippocampus Mercer et al., 1996 (398)  
Thalamus 
Mercer et al., 1996 (398) 
Emlquist et al., 1998 (180) 
 
Substantia Nigra 
Guan et al., 1997 (226) 
Figlewicz et al., 2003 (191) 
Tyrosine hydroxylase (TH) neurons (191) 
Ventral tegmental area (VTA) Figlewicz et al., 2003 (191) TH neurons (191) 
Cerebellum 
Guan et al 1997., (226) 
Emlquist et al., 1998 (180) 
 
Hindbrain 
- Area  postrema (AP) 
- Dorsal motor nucleus of the vagus (DMV) 
- Lateral parabrachial nucleus (lPB) 
- Nucleus of the solitary tract (NTS) 
-Spinal trigeminal tract 
- Spinal trigeminal nucleus 
Mercer et al., 1998 (400) 
 
CCK neurons (194, 209) 
GLP-1 (proglucagon) neurons (209) 
POMC neurons* (209) 
Choroid Plexus & Leptomeninges Mercer et al 1996 (398)  
*In POMC-EGFP mice  
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Table 3: Factors which influence leptin transport into the brain 
Increase Decrease 
Epinephrine (29) Obesity (77, 87) 
Glucose* (301) Fasting (300) 
Insulin* (301) Ovariectomy (302) 
Alcohol (441)  Triglycerides (30) 
CCK-8 (85) Lipopolysaccharide (425) 
Epidermal Growth Factor (23) c-reactive protein [CRP] (359) 
*Non-obese wild-type mice 
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Table 4: Mammalian CNS AdipoR1 Distribution. 
CNS expression site Reference Cell type 
Hypothalamus 
-Arcuate Nucleus 
- Lateral Hypothalamus 
-Paraventricular Nucleus 
- Supraoptic Nucleus 
- Preoptic area 
Guillod-Maximin et al., 2009(229) 
NPY/POMC neurons; astrocytes; ependymal 
cells (229) 
 
Warm sensitive neurons (316) 
Cortex Guillod-Maximin et al., 2009(229)  
Hippocampus Guillod-Maximin et al., 2009(229)  
Thalamus Guillod-Maximin et al., 2009(229)  
Striatum Guillod-Maximin et al., 2009(229)  
Pituitary Psilopanagioti et al., 2009 (462) GH, FSH, LH and TSH neurons 
Brainstem 
- Area  postrema 
- Nucleus of the solitary tract 
 
Fry et al., 2006 (200) 
Hoyda et al., 2009 (270) 
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Table 5: Mammalian CNS AdipoR2 Distribution 
CNS expression site Reference Cell type 
Hypothalamus 
-Arcuate Nucleus 
- Lateral Hypothalamus 
-Paraventricular Nucleus 
- Supraoptic Nucleus 
- Preoptic area 
Perifornical region 
Guillod-Maximin et al., 2009 (229) 
 
Klein et al., 2011 (316) 
NPY/POMC neurons; astrocytes (229) 
 
Warm sensitive neurons (316) 
Cortex Guillod-Maximin et al., 2009 (229)  
Hippocampus Guillod-Maximin et al., 2009 (229)  
Thalamus Guillod-Maximin et al., 2009 (229)  
Striatum Guillod-Maximin et al., 2009 (229)  
Pituitary Psilopanagioti et al., 2009 (462) GH, FSH, LH and TSH neurons 
Brainstem 
- Area  postrema 
- Nucleus of the solitary tract 
 
Fry et al., 2006 (200) 
Hoyda et al., 2009 (270) 
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Figure Legends 
Figure 1: Leptin-signaling in leptin-sensitive compared with leptin-resistant conditions 
Leptin-sensitive: Upon leptin binding to the extracellular domain of the receptor dimer, Janus 
kinase (JAK) 2 is activated resulting in phosphorylation of the intracellular domain of receptor at 
three tyrosine residues: 1) Phosphorylation of Tyr985 resulting in recruitment of Src-homology 2 
domain-containing phosphatase 2 (SHP2/PTPN1) leading to activation of the extracellular signal-
regulated kinases (ERK) signaling cascade (27, 89, 357); 2) Phosphorylation of Tyr1077 resulting 
in recruitment of the transcription factor Signal transducer and activator of transcription (STAT) 5 
(219) and 3) Phosphorylation of Tyr1138 resulting in recruitment of the transcription factor STAT3 
(27, 357, 579). Activation of Ob-Rb signaling also can result in activation of the 
phosphatidylinositol 3-kinase (PI3K) pathway via insulin receptor substrate (IRS) proteins (160, 
480). Negative feedback inhibition of Ob-Rb signaling is provided by suppressor of cytokine 
signaling (SOCS) 3 (53, 55, 164) binding at Try985 and PTP1B acting at Jak2 (106, 628). 
Leptin-resistant: Diet-induced obesity causes inflammation and ER stress in the brain (143, 438, 
561, 635). Obesity-associated inflammation and ER stress activate the nuclear factor-kappa B 
(NFκB) signaling pathway and c-Jun N-terminal kinase (JNK) in the brain (635). JNK inhibits IRS 
signaling. In the course of normal homeostatic leptin signaling, negative feedback inhibition of 
Ob-Rb signaling is provided by SOCS3 (53, 55, 164) and PTP1B binding (106, 628). Obesity is 
associated with elevated hypothalamic expression of both SOCS3 (53) and PTP1B (629). 
Expression of PTP1B is increased by inflammation (629) and ER stress (443) via the activation 
NFκB signaling suggesting providing a further link potential mechanistic link between 
inflammatory signaling and ER stress and the development of CNS leptin resistance.  
Solid blue arrows indicate activation; Dashed blue arrows indicate nuclear translocation; Red 
lines indicate an inhibitory action. 
 
Figure 1: Teaching Points 
Leptin signals through a tyrosine kinase linked receptor. The signaling mechanism is described in 
the formal figure legend. Phosphorylation of different tyrosine residues on the intracellular domain 
of the leptin receptor results in the activation of different downstream signaling pathways 
including kinases and transcription factors. These subsequently mediate a number of different 
downstream physiological events including modulation of neuroendocrine and autonomic 
pathways. Feedback inhibition of leptin receptor signaling is mediated via SOCS 3 and PTP1B. 
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When leptin levels are chronically elevated during obesity leptin signaling becomes less effective: 
a state known as leptin resistance. On a molecular level inflammation and ER stress associated 
with obesity lead to an enhancement of the inherent mechanisms inhibiting leptin signaling 
(SOCS3 and PTP1B) and also stimulation of JNK which inhibits leptin signaling via the IRS/PI3K 
pathway. 
 
Figure 2: Simplified diagram of CNS neurocircuits regulating energy and glucose 
homeostasis.  
A number of hypothalamic and extrahypothalamic sites have been implicated in the action of 
leptin in the regulation energy and glucose homeostasis. Due to the extensive neuronal 
interconnectivity between the brain nuclei in the diagram, for clarity, the neural projections 
between each site have not been indicated. The hypothalamic ARC contains neuropeptide Y and 
agouti-related peptide (NPY/AgRP) neurons that stimulate food intake and are inhibited by leptin, 
and proopiomelanocortin (POMC) neurons that reduce food intake and are stimulated by leptin. 
NPY/AgRP neurons also inhibit POMC neurons via synaptic release of the neurotransmitter 
GABA. POMC and AgRP neurons exert their effects on food intake via melanocortin 4 receptors 
(MC4R) expressed on downstream target neurons. 
ARC, arcuate nucleus; LepRb, leptin receptor; Mc3r/Mc4r, melanocortin-3/4 receptor; VMH, 
ventromedial hypothalamus; LHA, lateral hypothalamic area; PVN, paraventricular nucleus; DMH, 
dorsomedial hypothalamus; VTA, ventral tegmental area; NTS, nucleus of the solitary tract. 
Reprinted with permission from (410). 
 
Figure 2: Teaching points 
Leptin receptors are found in many different areas of the brain and important in regulating the 
regulation of food intake and body weight (energy homeostasis), and the control of blood glucose 
levels. This includes a number of areas within the hypothalamus but also non-hypothalamic areas 
of the brain including sites in the midbrain (VTA) and brainstem (NTS). The most well 
characterized and understood effects of leptin on glucose and energy homeostasis occur via its 
receptors expressed in the hypothalamus. In an area of the hypothalamus called the arcuate 
nucleus (ARC) neurons containing neuropeptide Y and agouti-related peptide [(NPY/AgRP) that 
stimulate food intake], and neurons containing proopiomelanocortin [(POMC) that reduce food 
intake]; both express leptin receptors. Leptin acts to decrease food intake by inhibiting the activity 
of NPY/AgRP neurons and increasing the activity of POMC neurons. Melanocortin 4 receptors 
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(MC4R) are important for mediating the downstream effects of POMC and NPY/AgRP neurons on 
food intake. In humans and animals, mutations in the POMC or MC4R gene cause profound 
obesity. 
 
Figure 3: Simplified schematic of adiponectin receptor signaling.  
AdipoR1/2 interacts with the adaptor protein APPL1 stimulating the insulin receptor substrate 1/2 
(IRS1/2) pathway leading to increased Akt (serine 473), Foxo1 (serine 256) and ERK (threonine 
202/tyrosine 204) phosphorylation. Activation of the receptor can also stimulate the JAK2-STAT3 
pathway, increasing STAT3 tyrosine 705 phosphorylation, translocation of dimerized STAT3 to 
the nucleus and activation of transcription. The adipokine can also activate the AMP-activated 
protein kinase (AMPK) via increasing intracellular calcium levels, leading to activation of 
calmodulin-dependent kinase kinase β (CamKKβ). Phosphorylation of AMPK (threonine 172) by 
CamKKβ, increases kinase activity and subsequent leads to phosphorylation of endothelial nitric 
oxide synthase (eNOS) at serine 1177 by AMPK. Adiponectin can also stimulate the stress 
activated MAP kinase pathway by stimulating phosphorylation of p38 MAPK. 
 
Figure 3: Teaching points 
Adiponectin receptors (AdipoR1/2) are seven transmembrane receptors but are not G-protein 
coupled. Activation of adiponectin receptors by adiponectin can lead to the activation of a number 
downstream signaling pathways, as described in the main figure legend. This includes kinases 
and transcription factors. AMPK, which is activated downstream of adiponectin receptors is a 
critical enzyme in the modulation of cellular energy levels regulating fatty acid uptake and β-
oxidation.  
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